PATH: Form 990, tax year 2018
View the entire original 990 at ProPublica ↗
- Organization
- PATH (EIN 91-1157127)
- Tax period
- 2018-01-01 to 2018-12-31
- Filed
- 2019-11-12
- IRS object ID
- 201923169349306077
- Schema version
- 2018v3.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2019-11-12T16:38:20-06:00 | ReturnTs |
| Tax Period End | 2018-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 521392008 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GELMAN ROSENBERG & FREEDMAN | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4550 MONTGOMERY AVE SUITE 800N | AddressLine1Txt |
| City | BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 208142930 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2018-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 911157127 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PATH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | PATH | BusinessNameControlTxt |
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | BRIAN NEVILLE | PersonNm |
| Person Title | CHIEF OF ACCOUNTING | PersonTitleTxt |
| Phone | 2062853500 | PhoneNum |
| Signature | 2019-11-12 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | RICHARD J LOCASTRO CPA | PreparerPersonNm |
| PTIN | P00288314 | PTIN |
| Phone | 3019519090 | PhoneNum |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 75.103.231.202 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2019-11-12 | IPDt |
| IP Tm | 17:38:15 | IPTm |
| IP Timezone | ES | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | 981DD7ACBC606C3C3562579832A13CC83ACA1B41 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 60F5620986AF14763908AFE7AC6F4ECEC523E148 | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2018 | TaxYr |
| Build TS | 2020-04-17 16:48:07Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | BRIAN NEVILLE | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $388,448,491 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1981 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III, LINE 1. | ActivityOrMissionDesc |
| Voting Members Governing Body | 14 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 14 | VotingMembersIndependentCnt |
| Total Employee | 787 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $547,406 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $347,844,394 | PYContributionsGrantsAmt |
| CY Contributions Grants | $305,315,221 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $41,949 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $1,500 | CYProgramServiceRevenueAmt |
| PY Investment Income | $2,168,657 | PYInvestmentIncomeAmt |
| CY Investment Income | $3,037,130 | CYInvestmentIncomeAmt |
| PY Other Revenue | $5,225,302 | PYOtherRevenueAmt |
| CY Other Revenue | $980,560 | CYOtherRevenueAmt |
| PY Total Revenue | $355,280,302 | PYTotalRevenueAmt |
| CY Total Revenue | $309,334,411 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $66,754,537 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $62,762,146 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $136,040,867 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $139,545,675 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $3,186,635 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $126,837,131 | PYOtherExpensesAmt |
| CY Other Expenses | $110,458,648 | CYOtherExpensesAmt |
| PY Total Expenses | $329,632,535 | PYTotalExpensesAmt |
| CY Total Expenses | $312,766,469 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $25,647,767 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | -$3,432,058 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $467,947,698 | TotalAssetsBOYAmt |
| Total Assets EOY | $237,501,233 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $50,797,492 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $202,931,874 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $417,150,206 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $34,569,359 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $128,263,294 | ExpenseAmt |
| Grant | $15,311,912 | GrantAmt |
| Revenue | $1,500 | RevenueAmt |
| Desc | GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION BRINGS TOGETHER OUR SIGNIFICANT COUNTRY EXPERIENCE AND DEEP TECHNICAL EXPERTISE TO FACILITATE THE ORGANIZATION'S ABILITY TO ACHIEVE IMPACT THROUGH INNOVATIVE APPROACHES AND SOLUTIONS. THIS DIVISION MANAGES PATH'S PRESENCE IN COUNTRY OFFICES AND IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; NONCOMMUNICABLE DISEASES; HEALTH SYSTEMS INNOVATION AND DELIVERY; AND DIGITAL HEALTH SOLUTIONS.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE THAT OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. APPROACHES PIONEERED BY PATH HAVE CONTRIBUTED TO REMARKABLE PROGRESS TOWARD CONTROLLING AND ELIMINATING MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2018, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA AS THEY STRIVE TO ACHIEVE THEIR MALARIA ELIMINATION GOALS. WE HELPED BY SCALING UP PREVENTION AND TREATMENT, EVALUATING SENSITIVE DIAGNOSTIC TOOLS, ESTABLISHING RAPID REPORTING SYSTEMS, AND SUPPORTING POPULATION-WIDE, DRUG-BASED STRATEGIES, SUCH AS MASS DRUG ADMINISTRATION. THROUGH OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES, PATH ASSISTED THE GOVERNMENT OF ZAMBIA IN REACHING ITS GOALS FOR ELIMINATING LOCAL MALARIA INFECTION AND DISEASE. THIS WORK FOCUSED ON BEDNETS, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, CASE MANAGEMENT, SURVEILLANCE, AND MONITORING & EVALUATION. THE PROGRAM'S GEOGRAPHIC FOCUS IS ON PROVINCES WITH THE HIGHEST MALARIA PREVALENCE AMONG CHILDREN.PATH ALSO WORKED TO IMPROVE DATA FOR MALARIA CONTROL DECISION-MAKING AND SURVEILLANCE. IN ZAMBIA, FOR EXAMPLE, THE VISUALIZE NO MALARIA PROJECT-A GROUNDBREAKING PARTNERSHIP WITH A SEATTLE-BASED SOFTWARE COMPANY AND A COALITION OF OTHER TECHNOLOGY COMPANIES-CONTINUED TO EXPAND. THIS PROJECT EQUIPS HEALTH WORKERS AND OFFICIALS WITH REAL-TIME DATA VISUALIZATION TOOLS TO SEE WHERE MALARIA IS APPEARING SO THEY CAN DEPLOY RESOURCES TO HALT ITS SPREAD. IN WESTERN KENYA, PATH ASSESSED THE POTENTIAL CONTRIBUTION OF MALARIA TESTING DATA FROM PREGNANT WOMEN ATTENDING ANTENATAL CLINICS AS A MEANS TO BOLSTER SURVEILLANCE.IN 2018, PATH ALSO WORKED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S MALARIA VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. VACCINATIONS ARE DUE TO BEGIN IN 2019. PATH CONTINUED TO DEVELOP AND EVALUATE NEW VECTOR-CONTROL TOOLS SUCH AS NEXT-GENERATION INDOOR RESIDUAL SPRAYING (IN PARTNERSHIP WITH THE INNOVATIVE VECTOR CONTROL CONSORTIUM, THE US PRESIDENT'S MALARIA INITIATIVE, ABT ASSOCIATES, AND THE GLOBAL FUND). THIS WORK IS GENERATING EVIDENCE TO SUPPORT TIMELY DECISION-MAKING AROUND THE ADOPTION OF NEW INSECTICIDES THAT ARE EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. PATH ALSO LED EVALUATION AND DATA-FOR-DECISION-MAKING ACTIVITIES UNDER VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP VECTOR-CONTROL PARTNERSHIP. IN ADDITION, WE DIRECTED EVIDENCE-GENERATION ACTIVITIES UNDER THE NEW NETS PROJECT, FUNDED BY UNITAID AND THE GLOBAL FUND, TO HELP SCALE UP ACCESS TO AND USE OF NEW LONG-LASTING INSECTICIDE-TREATED NETS.TO ADDRESS THE TWIN THREATS OF INSECTICIDE RESISTANCE AND OUTDOOR BITING BY MOSQUITOES, PATH CONTINUED THE DEVELOPMENT AND EVALUATION OF ATTRACTIVE TARGETED SUGAR BAITS, WHICH PRESENT A SUGAR MEAL FOR MOSQUITOES THAT IS LACED WITH AN INSECTICIDE. PATH ALSO SUPPORTED THE DEVELOPMENT OF A NEW, HIGHLY SENSITIVE RAPID DIAGNOSTIC TEST THAT OFFERS A GREATER THAN TENFOLD IMPROVEMENT IN DETECTION OF THE MOST COMMON MALARIA PARASITE. FINALLY, WE ADVANCED WORK ON A POINT-OF-CARE DIAGNOSTIC TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY, A CONDITION THAT CAN COMPLICATE MALARIA TREATMENT.IN PATH'S EFFORTS TO FIGHT NEGLECTED TROPICAL DISEASES, OUR WORK INCLUDES DEFINING PRODUCT NEEDS; DEVELOPING TARGET PRODUCT PROFILES; ENGAGING WITH STAKEHOLDERS; CONDUCTING LABORATORY AND FIELD TESTS AND EVALUATIONS; TRANSFERRING TECHNOLOGY AND SECURING MANUFACTURING, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS; COMMERCIALIZING PRODUCTS AND COLLATERAL; AND SUPPORTING PRODUCT LAUNCH. MUCH OF THIS WORK IS ACCOMPLISHED VIA PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION.HIV AND TUBERCULOSISPATH CONTINUED TO CONTRIBUTE TO HIV PREVENTION AND EPIDEMIC CONTROL IN 2018 BY FOCUSING PROGRAMMING ON THE KEY AND HIGH-PRIORITY POPULATIONS OF ADOLESCENT GIRLS AND YOUNG WOMEN, PEOPLE WITH BOTH HIV AND TUBERCULOSIS (TB), SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, AND TRANSGENDER INDIVIDUALS. WE ADVANCED PROGRAMMING ACROSS MULTIPLE TECHNOLOGY AND SERVICE DELIVERY PLATFORMS-FROM DEVICES, TOOLS, AND DIAGNOSTICS TO SERVICE DELIVERY INNOVATIONS AND ADVOCACY. PATH'S WORK IN DIAGNOSTICS FOCUSED ON FILLING GAPS IN FOUR CRITICAL AREAS: SELF-TESTING, EARLY INFANT DIAGNOSIS, TB DETECTION AMONG PEOPLE LIVING WITH HIV, AND VIRAL LOAD DETECTION. WE FOCUSED ON UNDERSTANDING THE BARRIERS THAT RESTRICT ACCESS TO HIGH-QUALITY DIAGNOSTICS AND ADVANCING NEW PRODUCTS TO OVERCOME THESE OBSTACLES. TO INFORM DESIGN AND DELIVERY OF NEXT-GENERATION HIV SELF-TESTS, PATH EMPLOYED USER-CENTERED DESIGN METHODOLOGIES TO CREATE USER PERSONAS REPRESENTING KEY POPULATIONS. PATH ALSO WORKED TO EVALUATE AND ADVANCE DEVICES TO PROVIDE LONG-TERM ANTIRETROVIRAL DELIVERY FOR PRE-EXPOSURE PROPHYLAXIS (PREP) AND HIV TREATMENT. THESE DEVICES INCLUDE MICROARRAY PATCHES FOR TRANSDERMAL DELIVERY AND AN APPLICATOR TO SUBCUTANEOUSLY INSERT BIODEGRADABLE IMPLANTS. WE ALSO WORKED ON A PEDIATRIC-FRIENDLY DOSAGE FORM OF ANTIRETROVIRAL DRUGS, USING OUR FAST-DISSOLVING TABLET TECHNOLOGY.THROUGH THE AIDS, POPULATION, AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS PROJECT), PATH HELPED TO INTEGRATE HEALTH SERVICES IN WESTERN KENYA AND ENABLE MORE PEOPLE TO ACCESS A GREATER SPECTRUM OF SERVICES. SINCE 2011, THE PATH-LED TEAM HAS BUILT THE CAPACITY OF HEALTH CARE WORKERS AND FACILITIES TO DELIVER HIGH-QUALITY SERVICES FOR HIV, TB, SEXUAL AND REPRODUCTIVE HEALTH, AND ADOLESCENT HEALTH; STRENGTHENED LINKAGES BETWEEN HEALTH FACILITIES AND COMMUNITIES TO EXPEDITE ACCESS TO HIV CARE AND TREATMENT; ESTABLISHED COMMUNITY SUPPORT SYSTEMS FOR PEOPLE LIVING WITH HIV AND THEIR FAMILIES; AND EMPOWERED AND MOBILIZED COMMUNITIES AROUND HIV PREVENTION AND OUTREACH.IN 2018, PATH TRANSITIONED HIV ACTIVITIES IN KENYA'S FORMER NYANZA PROVINCE TO USAID'S PATH-LED AFYA ZIWANI PROJECT, WHILE CONTINUING HIV AND TB SERVICE DELIVERY IN THE FORMER WESTERN PROVINCE THROUGH APHIAPLUS. WITH FUNDING FROM THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF DREAMS INITIATIVE, APHIAPLUS AND THE AFYA ZIWANI PROJECT INTENSIFIED EFFORTS TO REACH MORE THAN 77,500 ADOLESCENT GIRLS AND YOUNG WOMEN IN KENYA WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES. THIS WORK INCLUDED THE CREATION OF MORE THAN 200 SAFE SPACES AND IMPROVED ACCESS TO YOUTH-FRIENDLY FAMILY PLANNING, HIV, AND GENDER-BASED VIOLENCE SERVICES. IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), PATH CONTINUED TO LEAD USAID-FUNDED EFFORTS TO IMPROVE HIV/AIDS SERVICES. IN 2018, THIS WORK FOCUSED ON TWO HIGH-PREVALENCE PROVINCES UNDER THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA AND LUALABA. PATH PROVIDED TECHNICAL ASSISTANCE TO 162 HEALTH FACILITIES, 18 HEALTH ZONES, AND 5 NONGOVERNMENTAL ORGANIZATIONS TO INCREASE TARGETED TESTING EFFORTS, ENROLL ALL IDENTIFIED HIV-POSITIVE INDIVIDUALS ON TREATMENT, SCALE UP VIRAL LOAD TESTING, AND ROLL OUT DIFFERENTIATED CARE MODELS TO IMPROVE RETENTION IN TREATMENT. AT THE END OF DECEMBER 2018, PATH WAS SUPPORTING MORE THAN 33,000 INDIVIDUALS IN THE DRC ON ANTIRETROVIRAL THERAPY. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $88,257,285 | ExpenseAmt |
| Grant | $37,275,906 | GrantAmt |
| Desc | ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES GLOBALLY AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATHS AND DISEASES WORLDWIDE.FOR EXAMPLE, IN 2018 WE CONTINUED TO PARTNER WITH COUNTRIES TO EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINE, WHICH PATH HELPED SHEPHERD THROUGH THE GLOBAL REGULATORY PROCESS AND SCALE UP. WITH SUPPORT FROM PATH, THE GOVERNMENT OF INDONESIA LAUNCHED JE VACCINATION CAMPAIGNS IN THE PROVINCE OF BALI. PATH ALSO PROVIDED TECHNICAL ASSISTANCE IN THE LEAD-UP TO JE VACCINATION CAMPAIGNS IN SELECT, HIGH-RISK REGIONS IN THE PHILIPPINES.IN 2018, WE CONTINUED A PHASE 2 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS VACCINE IN YOUNG CHILDREN IN MALI. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A VACCINE AGAINST MENINGOCOCCAL MENINGITIS SEROGROUP A THAT WAS LICENSED AND INTRODUCED IN 2010. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. THE VACCINE IS DESIGNED FOR USE IN THE AFRICAN "MENINGITIS BELT" REGION AND WILL BE THE FIRST VACCINE TO TARGET SEROGROUP X. TO PREVENT MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2018, PATH CONTINUED TO WORK WITH WHO AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. WITH PARTNERS, PATH CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. FIELD TESTING OF THE DELAYED FRACTIONAL DOSE REGIMEN BEGAN AT A RESEARCH CENTER IN KENYA IN 2018.PATH'S DEFEAT DIARRHEAL DISEASE INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ONGOING WORK TO GENERATE INVESTMENTS IN ROTAVIRUS, ENTEROTOXIGENIC ESCHERICHIA COLI, AND SHIGELLA VACCINES WITHIN THE CONTEXT OF AN INTEGRATED PREVENTION AND TREATMENT APPROACH. THE PROJECT RECEIVED STANDALONE FUNDING IN LATE 2018 TO CONTINUE EDUCATING OUR TARGET AUDIENCES ON THE LIFELONG CONSEQUENCES OF REPEATED INFECTIONS. IN 2018, PATH ALSO HELPED INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ENTERIC VACCINES, INCLUDING THE NEWLY WHO-PREQUALIFIED ROTAVAC AND ROTASIIL ROTAVIRUS VACCINES AND TYPBAR-TCV TYPHOID CONJUGATE VACCINE. PATH LED AND/OR SUPPORTED ONGOING PHASE 4 CLINICAL TRIALS, CONDUCTED VACCINE IMPACT AND COST-EFFECTIVENESS ANALYSES, AND DISSEMINATED EVIDENCE THROUGH ADVOCACY AND COMMUNICATIONS TO INFORM COUNTRY DECISION-MAKING AROUND VACCINE INTRODUCTION AND PRODUCT SWITCHES.IN 2018, PATH CONTINUED TO SUPPORT SOUTH AFRICAN VACCINE MANUFACTURER THE BIOVAC INSTITUTE IN PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. THE INTENDED VACCINE POPULATION IS PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. ALSO IN 2018, PATH CONTINUED A PROJECT TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE AND SYNTHESIZE EXISTING EVIDENCE AND EVALUATE NEW DATA ON THE POTENTIAL FOR SINGLE-DOSE HPV VACCINATION. ALTHOUGH MANY COUNTRIES HAVE INTRODUCED HPV VACCINES INTO THEIR NATIONAL IMMUNIZATION SCHEDULES, SOME LOW- AND LOWER-MIDDLE-INCOME COUNTRIES HAVE DELAYED INTRODUCTION BECAUSE OF FINANCIAL, LOGISTICAL, OR OTHER BARRIERS. FOR THESE COUNTRIES, A SINGLE-DOSE REGIMEN COULD ACCELERATE INTRODUCTION OF HPV VACCINES INTO NATIONAL IMMUNIZATION SCHEDULES.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS TO ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN LIVING IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. WE WORK TO ADVANCE THE MOST PROMISING SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO POLICY INTRODUCTION.IN 2018, IN COLLABORATION WITH PARTNERS, PATH CONTINUED TO ADVANCE A PORTFOLIO OF DRUG PROJECTS TO REDUCE THE GLOBAL BURDEN OF ENTERIC AND DIARRHEAL DISEASE AMONG YOUNG CHILDREN. FOR EXAMPLE, WE MADE SIGNIFICANT PROGRESS IN VALIDATING A NEW RESEARCH ASSESSMENT TOOL FOR ENVIRONMENTAL ENTERIC DYSFUNCTION (EED)-AN INTESTINAL DISORDER COMMON AMONG CHILDREN LIVING IN LOW-RESOURCE SETTINGS THAT IS ASSOCIATED WITH INCREASED RISK OF STUNTING, COGNITIVE DEFICITS, AND REDUCED RESPONSIVENESS TO ORAL VACCINES. THE TOOL IS DESIGNED TO MEASURE MULTIPLE BIOMARKERS, INCLUDING THOSE OF EED, SYSTEMIC INFLAMMATION, GROWTH HORMONE RESISTANCE, AND MICRONUTRIENTS, AND COULD BE AN ASSET FOR EED CLINICAL RESEARCH IN LOW-INCOME COUNTRIES. THE DIARRHEA INNOVATIONS GROUP (DIG), AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED ITS WORK TO IMPROVE COLLABORATION FOR DIARRHEAL DISEASE RESEARCH AND ACCELERATE PROGRESS THROUGH PARTNERSHIPS. IN NOVEMBER 2018, DIG MEMBERS PETITIONED WHO TO INCLUDE CO-PACKAGED ORAL REHYDRATION SOLUTION (ORS) AND ZINC IN ITS MODEL LIST OF ESSENTIAL MEDICINES. JOINT ADMINISTRATION OF ORS AND ZINC HAS LONG BEEN RECOMMENDED FOR MANAGEMENT OF PEDIATRIC DIARRHEA, YET NO FORMAL GUIDANCE ON CO-PACKAGED ORS-ZINC EXISTED, AND THE NUMBER OF CHILDREN WITH DIARRHEA RECEIVING THE OPTIMAL TREATMENT REMAINS UNACCEPTABLY LOW AT LESS THAN 7 PERCENT. ONCE ADOPTED BY WHO, THIS GLOBAL POLICY CHANGE WILL HELP PRIORITIZE BOTH ORS AND ZINC AS THE DIARRHEA MANAGEMENT STANDARD AT THE NATIONAL LEVEL, ULTIMATELY IMPROVING COVERAGE AND SAVING LIVES.ALSO IN 2018, WE CONTINUED OUR WORK TO DEVELOP NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, ONE OF THE KEY PATHOGENS RESPONSIBLE FOR DIARRHEAL MORBIDITY IN CHILDREN UNDER FIVE YEARS OF AGE. IN ADDITION, WE PREPARED FOR A STUDY TO TEST THE INVESTIGATIONAL NEW DRUG IOWH032 AS AN ANTISECRETORY THERAPY FOR THE TREATMENT OF CHOLERA.PARALLEL TO DRUG RESEARCH AND DEVELOPMENT, PATH CONTINUED OUR WORK TO ENSURE THAT ESSENTIAL MEDICINES ARE RELIABLY ACCESSIBLE TO THE PEOPLE WHO NEED THEM. OUR ACCESS TO ESSENTIAL MEDICINES INITIATIVE CARRIED OUT AN IN-DEPTH ANALYSIS OF THE WHO ESSENTIAL MEDICINES LISTS AND DEVELOPED A TOOL TO HELP IDENTIFY AND PRIORITIZE MEDICINES WITH SUBOPTIMAL ACCESS AND USE. THE TOOL IS DESIGNED TO HELP GLOBAL AND COUNTRY STAKEHOLDERS BETTER UNDERSTAND ACCESS GAPS AND THE HEALTH IMPACT POTENTIAL OF ESSENTIAL MEDICINES. THIS, IN TURN, CAN GUIDE DECISION-MAKING ON ACTIVITIES AND INVESTMENTS. IN 2018, WE INTRODUCED THE TOOL TO A NUMBER OF PARTNERS AND FUNDERS AND EXPLORED OPPORTUNITIES TO MAKE IT PUBLICLY AVAILABLE. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $26,496,089 | ExpenseAmt |
| Grant | $4,929,933 | GrantAmt |
| Desc | TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION BEGAN THE YEAR AS TECHNOLOGY DEVELOPMENT AND INTRODUCTION (TDI). AS SUCH, IT WAS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT DEVICES, TOOLS, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. IN JULY 2018, TDI GREW TO INCLUDE ADDITIONAL PROGRAMS-SUCH AS MARKET DYNAMICS, DIGITAL & DATA, AND MONITORING & EVALUATION-AND WAS RENAMED TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI).(CONTINUED ON SCHEDULE O)DEVICES AND TOOLSTHE DEVICES AND TOOLS PROGRAM WITHIN TAMI IS PATH'S INNOVATIVE PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.IN 2018, THE PROGRAM'S MILESTONES INCLUDED TRANSFERRING THE DESIGN OF THE BUBBLE CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE AND OXYGEN BLENDER TO A MANUFACTURER, BEGINNING FIELD EVALUATIONS FOR A FREEZE-SAFE VACCINE CARRIER IN NEPAL WITH A STUDY PARTNER, AND COMPLETING A PROGRAMMATIC AND HUMAN FACTORS EVALUATION OF THREE BLOW-FILL-SEAL VACCINE CONTAINERS IN AFRICA AND ASIA, AS WELL AS RECLASSIFICATION OF THE FEMALE CONDOM BY THE US FOOD & DRUG ADMINISTRATION FROM A CATEGORY III TO CATEGORY II MEDICAL DEVICE.STAFF PRODUCED 17 JOURNAL ARTICLES AND REPORTS ON RESEARCH FINDINGS, RANGING FROM ASSESSMENTS OF TECHNOLOGIES TO IMPROVE IMMUNIZATION TO EVALUATIONS OF NEONATAL RESUSCITATORS.DIAGNOSTICSPATH'S WORK TO ADVANCE ACCURATE DIAGNOSTIC TECHNOLOGIES THAT STRENGTHEN HEALTH EQUITY INCLUDES TOOLS TO DETECT AND MONITOR NEGLECTED TROPICAL DISEASES, MALARIA, HIV, POLIO, AND NONCOMMUNICABLE DISEASES.IN 2018, OUR PIONEERING WORK IN MALARIA DIAGNOSTICS INCLUDED DEVELOPING NEW TOOLS TO IMPROVE DETECTION OF THE MALARIA PARASITE AND TESTS TO GUIDE THE CLINICAL CARE OF PATIENTS. WITH OUR RESEARCH AND DEVELOPMENT PARTNERS, PATH ADVANCED SEVERAL POINT-OF-CARE TESTS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. THIS INCLUDED COMPLETING FIELD-BASED STUDIES OF A QUANTITATIVE BIOSENSOR AND FACILITATING A COMMUNITY OF PRACTICE FOR GLOBAL RESEARCHERS WORKING TO ADVANCE G6PD DIAGNOSTICS. PATH DEVELOPED GEODX, A COMPUTER PROGRAM THAT ESTIMATES THE PLASMODIUM VIVAX BURDEN PER HEALTH FACILITY, THE TOTAL QUANTITY OF G6PD TESTS THAT WOULD BE REQUIRED PER COUNTRY, AND THE ASSOCIATED COST. ADDITIONALLY, WE COMPLETED VALIDATION OF A MULTIPLEXED ARRAY THAT MEASURES MULTIPLE MALARIA ANTIGENS AT LOW CONCENTRATIONS TO SUPPORT THE DEVELOPMENT OF IMPROVED RAPID DIAGNOSTIC TESTS.WITH PARTNERS, PATH ESTABLISHED A BIOREPOSITORY TO SUPPORT THE DEVELOPMENT OF IMPROVED PREECLAMPSIA DIAGNOSTICS. ADDITIONALLY, PATH CREATED NEW TRAINING MATERIALS, INCLUDING A USER AID, TO SUPPORT OPERATIONS RESEARCH ON AN IMPROVED PREECLAMPSIA TEST.IN COLLABORATION WITH A PRIVATE-SECTOR PARTNER, PATH WORKED TO SIGNIFICANTLY LOWER THE PRICE PER ANALYTE FOR A MULTIPLEXED TOOL THAT DETECTS UP TO SEVEN NUTRITION- AND DISEASE-RELATED BIOMARKERS FOR POPULATION-BASED SURVEILLANCE OF MICRONUTRIENT DEFICIENCIES.FURTHER, PATH AND OUR PARTNERS CONDUCTED FIELD STUDIES AND MARKET RESEARCH TO ASSESS AND VALIDATE THE APPLICATION OF A BOVINE ESTRUS DETECTION TEST IN LOW- AND MIDDLE-INCOME COUNTRIES TO IMPROVE LIVELIHOODS AND NUTRITION. THE PRODUCT WAS LAUNCHED WITH DISTRIBUTION PARTNERS IN KENYA, TANZANIA, AND UGANDA.IMPACT LABSPATH'S IMPACT LABS IN INDIA, KENYA, AND SOUTH AFRICA HELP TO ADVANCE THE MOST PROMISING HEALTH TECHNOLOGIES. THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON INNOVATIVE PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. THROUGH OUR NETWORK OF IMPACT LABS, PATH CAN LEVERAGE WORLD-CLASS GLOBAL AND COUNTRY EXPERTISE TO ACCELERATE THE DEVELOPMENT AND INTRODUCTION OF SCALABLE DEVICES, TOOLS, AND DIAGNOSTICS FOR HEALTH. THE KENYA IMPACT LAB WAS IN NASCENT STAGES IN 2018; ACTIVITIES FOR INDIA AND SOUTH AFRICA ARE DESCRIBED BELOW. THE INDIA IMPACT LAB WAS OFFICIALLY LAUNCHED IN JANUARY 2018 IN PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI AS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY (MEDTECH) INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE-UP. IN JULY 2018, THE IMPACT LAB LAUNCHED A 12-MONTH INTENSIVE PROGRAM: SOCIAL ALPHA QUEST FOR HEALTHCARE INNOVATIONS. THE QUEST FEATURED A SYSTEMATIC, COHORT-BASED ENGAGEMENT MODEL WITH TEN SELECTED MEDTECH PRODUCT START-UPS. THE PROGRAM PROVIDED THE START-UPS WITH CONTEXTUAL SUPPORT, GUIDANCE, AND MENTORSHIP IN PRODUCT DEVELOPMENT, CLINICAL EVIDENCE GENERATION, REGULATIONS, QUALITY MANAGEMENT, MARKET UNDERSTANDING, AND PROCUREMENT CHANNELS. THE IMPACT LAB PARTNERED AND SIGNED MEMORANDUMS OF UNDERSTANDING WITH FIVE TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES TO CONDUCT JOINT PROGRAMS FOR THE DEVELOPMENT OF THE INNOVATION ECOSYSTEM. THE IMPACT LAB ALSO DELIVERED EIGHT CURATED AND FOCUSED KNOWLEDGE PLATFORMS (FOR EXAMPLE, WORKSHOPS, ROUNDTABLES, AND MENTOR MIXERS). FOR THESE, THE IMPACT LAB ENGAGED EXPERTS FROM NUMEROUS LARGE AND SMALL MEDTECH COMPANIES. IN 2018, 60 TO 100 START-UPS PARTICIPATED IN EACH KNOWLEDGE PLATFORM (PRODUCT DEVELOPMENT, LOCAL AND GLOBAL REGULATIONS, STANDARDS, TESTING AND CALIBRATIONS, CERTIFICATION, VENDOR MANAGEMENT, QUALITY MANAGEMENT, AND MARKET ENTRY ASPECTS)-ALL HIGHLY RELEVANT TO THE GROWTH OF MEDTECH START-UPS AND THE INNOVATION ECOSYSTEM.FOR THE SOUTH AFRICA IMPACT LAB, A PRIMARY FOCUS OF 2018 WAS TO RE-ENGAGE AND RE-AFFIRM PATH'S RELATIONSHIP WITH THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) AND COMMITMENT TO OUR JOINT GLOBAL HEALTH INNOVATION ACCELERATOR (GHIA) PARTNERSHIP. FOR EXAMPLE, PATH FACILITATED A WORKSHOP WITH THE SAMRC REGARDING KEY COMMERCIALIZATION AND MARKET DYNAMICS CONCEPTS. WE ALSO PROVIDED TECHNICAL ASSISTANCE TO THE SAMRC AND OTHER PARTNERS ON A SUCCESSFUL GRAND CHALLENGES CANADA APPLICATION FOR A MATERNAL HEALTH MEDICAL DEVICE. THESE AND OTHER ACTIVITIES WERE CONDUCTED UNDER A GRANT FROM THE BILL & MELINDA GATES FOUNDATION TO THE SAMRC. THE GRANT WAS AIMED AT BUILDING GHIA'S CAPACITY TO IMPROVE THE AFFORDABILITY AND AVAILABILITY OF HEALTH CARE SERVICES BY SUPPORTING THE DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL TECHNOLOGIES DESIGNED FOR RESOURCE-LIMITED SETTINGS IN SOUTH AFRICA AND BEYOND.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT AND INTRODUCTION. IT BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION, ALIGNS EXPERTISE ACROSS TEAMS, AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. IN 2018, OUR WORK FOCUSED ON ASSESSING MARKETS AND IMPROVING MARKET FUNCTIONING FOR MALARIA DRUGS AND DRUG INTERMEDIATES, MALARIA DIAGNOSTICS, OXYGEN THERAPY DEVICES, AND DEVICES FOR TREATMENT OF PRECANCEROUS CERVICAL LESIONS. THE MARKET DYNAMICS PROGRAM ALSO COLLABORATED WITH THE ADVOCACY AND PUBLIC POLICY TEAM TO STRENGTHEN MARKETS FOR MATERNAL AND NEWBORN HEALTH PRODUCTS THROUGH POLICY ADVOCACY. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $25,764,391 | ExpenseAmt |
| Grant | $5,244,395 | GrantAmt |
| Desc | ADVOCACY AND PUBLIC POLICY:PATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, GLOBALLY WITH MULTILATERAL AGENCIES ENGAGED IN HEALTH POLICY AND PLANNING, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2018, PATH LED ADVOCACY EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES AND EUROPE FOR RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH SECURITY. ONE EXAMPLE OF OUR SUCCESS WAS PASSAGE OF TWO POLICIES IN THE UNITED STATES THAT SOLIDIFIED US GOVERNMENT SUPPORT FOR RESEARCH AND DEVELOPMENT IN ITS GLOBAL HEALTH PROGRAMS. THANKS IN PART TO PATH'S EFFORTS TO EDUCATE MEMBERS OF CONGRESS, US GOVERNMENT FUNDING WAS MAINTAINED OR INCREASED FOR MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH RESEARCH AND DEVELOPMENT PROGRAMS.WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS DURING 2018, IN KENYA, YEARS OF ADVOCACY BY PATH RESULTED IN PASSAGE OF THE FIRST COMPREHENSIVE POLICY THAT HARMONIZES DELIVERY OF HEALTH CARE FOR CHILDREN FROM BIRTH THROUGH ADOLESCENCE. IN THE DRC, A NATIONAL STRATEGY AND A SUBNATIONAL POLICY WERE ADOPTED TO PRIORITIZE ELIMINATION OF HUMAN AFRICAN TRYPANOSOMIASIS, ALSO KNOWN AS SLEEPING SICKNESS. IN SOUTH AFRICA, PATH'S ADVOCACY INFLUENCED THE PRIORITIZATION OF RESEARCH AND DEVELOPMENT FOR HEALTH IN A NATIONAL POLICY FOR SCIENCE, TECHNOLOGY, AND INNOVATION. AND IN UGANDA, PATH SUCCESSFULLY ADVOCATED FOR FUNDS TO BE ALLOCATED FOR VACCINE DISTRIBUTION.SPECIAL INITIATIVES:PATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2018, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS: MALARIA; HIV/AIDS; MATERNAL, NEWBORN, AND CHILD HEALTH; NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; EPIDEMIC PREPAREDNESS AND RESPONSE/GLOBAL HEALTH SECURITY INNOVATION; AND HEALTH SYSTEMS STRENGTHENING/PRIMARY HEALTH CARE. EACH HEALTH IMPACT TEAM GOES THROUGH A STAGED PROCESS OF SCALE-UP AND GROWTH. THESE TEAMS DEVELOP AND EVOLVE STRATEGY, STRENGTHEN AND CONNECT PATH TALENT ACROSS GEOGRAPHIES AND PROGRAMS, AND FOCUS ON REVENUE GENERATION FOR PATH THROUGH EXTERNAL ENGAGEMENT AND POSITIONING WITH KEY PARTNERS AND DONORS. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $25,764,391 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $5,244,395 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $268,781,059 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (1) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 230 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 787 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | Yes (1) | UnrelatedBusIncmOverLimitInd |
| Form990 T Filed | Yes (1) | Form990TFiledInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | BE | ForeignCountryCd |
| Foreign Country | CH | ForeignCountryCd |
| Foreign Country | CG | ForeignCountryCd |
| Foreign Country | ET | ForeignCountryCd |
| Foreign Country | GH | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | BM | ForeignCountryCd |
| Foreign Country | MZ | ForeignCountryCd |
| Foreign Country | PE | ForeignCountryCd |
| Foreign Country | SG | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | TZ | ForeignCountryCd |
| Foreign Country | UG | ForeignCountryCd |
| Foreign Country | UK | ForeignCountryCd |
| Foreign Country | UP | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | ZA | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 14 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 14 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BRIAN NEVILLE CHIEF OF ACCOUNTING | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVE SUITE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (33 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DAVID KING | |||||||||
| CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| FELIX OLALE | |||||||||
| VICE CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| YEHONG ZHANG | |||||||||
| SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| BRUCE MCNAMER | |||||||||
| TREASURER | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DEAN ALLEN | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| PEGGY JOHNSON | |||||||||
| DIRECTOR (UNTIL 12/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| GARY LOCKE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JO ADDY | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| IREENA VITTAL | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DEANNA OPPENHEIMER | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOEL HOLSINGER | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN-ARNE ROTTINGEN | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| HELENA WAYTH | |||||||||
| DIRECTOR (BEGAN 6/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| TSITSI MASIYIWA | |||||||||
| DIRECTOR (UNTIL 3/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DENNIS SCHMATZ | |||||||||
| DIRECTOR (UNTIL 3/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| BETH GALETTI | |||||||||
| DIRECTOR (BEGAN 12/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| SANFORD MELZER | |||||||||
| DIRECTOR (BEGAN 12/2018) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| STEPHEN B DAVIS | |||||||||
| PRESIDENT AND CEO | 38.00 | 2.00 | Yes (X) | $665,877 | $0 | $62,780 | |||
| OLIVIA D POLIUS | |||||||||
| CHIEF FINANCIAL OFFICER | 38.00 | 2.00 | Yes (X) | $320,646 | $0 | $51,936 | |||
| DANIEL LASTER | |||||||||
| COO AND GENERAL COUNSEL | 38.00 | 2.00 | Yes (X) | $310,669 | $0 | $41,544 | |||
| DAVID C KASLOW | |||||||||
| VP - PRODUCT DEVELOPMENT | 38.00 | 2.00 | $379,045 | $0 | $65,678 | Yes (X) | |||
| AMIE E BATSON | |||||||||
| CHIEF STRATEGY OFFICER | 39.00 | 1.00 | $378,150 | $0 | $22,577 | Yes (X) | |||
| KATHY CAHILL | |||||||||
| VP - INTERNATIONAL DEVELOPMENT | 40.00 | 0.00 | $345,013 | $0 | $26,620 | Yes (X) | |||
| DAVID W FLEMING | |||||||||
| VP - PUBLIC HEALTH IMPACT | 40.00 | 0.00 | $286,869 | $0 | $50,611 | Yes (X) | |||
| KATHRYN A O'DRISCOLL | |||||||||
| CHIEF HUMAN RESOURCES OFFICER | 40.00 | 0.00 | $279,820 | $0 | $27,714 | Yes (X) | |||
| ERICA J SESSLE | |||||||||
| CHIEF OF STAFF | 40.00 | 0.00 | $214,378 | $0 | $34,734 | Yes (X) | |||
| PRAVEEN RAJA | |||||||||
| VP - TECH. DEV. & INNOVATION | 40.00 | 0.00 | $333,003 | $0 | $31,412 | Yes (X) | |||
| ELAINE L GIBBONS | |||||||||
| VP - GLOBAL ENGAGEMENT | 40.00 | 0.00 | $265,826 | $0 | $65,813 | Yes (X) | |||
| JEFFREY D BERSON | |||||||||
| ASSOCIATE DIRECTOR II | 40.00 | 0.00 | $431,451 | $0 | $82,104 | Yes (X) | |||
| JAMES B MCKENNA | |||||||||
| ASSOCIATE DIRECTOR II | 40.00 | 0.00 | $396,308 | $0 | $75,232 | Yes (X) | |||
| TRAD M HATTON | |||||||||
| CHIEF OF PARTY | 40.00 | 0.00 | $321,206 | $0 | $48,784 | Yes (X) | |||
| BRUCE LAMONT INNIS | |||||||||
| GLOBAL DISEASE AREA HEAD | 40.00 | 0.00 | $311,376 | $0 | $26,645 | Yes (X) | |||
| JOHN O KONZ | |||||||||
| GLOBAL INT. PORT/FIN MGMT. CVIA HEAD | 40.00 | 0.00 | $299,215 | $0 | $64,603 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,538,852 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $778,787 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 340 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd |
|---|---|---|---|---|---|---|---|---|---|
| WIDENET CONSULTING GROUP LLC | |||||||||
| 2910 1ST AVE S 200 | SEATTLE | WA | 98134 | CONSULTING | $821,832 | ||||
| RANDSTAD INDIA PVT LTD | |||||||||
| STAFFING SERVICES | $715,744 | BLDG 9 STES 001/002 JASOLA | NEW DELHI | IN | 110025 | ||||
| WMBE PAYROLLING DBA TARGET CW | |||||||||
| 9475 CHESAPEAKE DRIVE | SAN DIEGO | CA | 92123 | GENERAL CONTRACTOR | $564,411 | ||||
| SLALOM LLC | |||||||||
| 821 2ND AVE SUITE 1900 | SEATTLE | WA | 98104 | CONSULTING | $488,798 | ||||
| UNIFY CONSULTING LLC | |||||||||
| 1518 1ST AVE S STE 201 | SEATTLE | WA | 98134 | CONSULTING | $471,870 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 51 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $23,547,825 | RelatedOrganizationsAmt |
| Government Grants | $112,897,926 | GovernmentGrantsAmt |
| All Other Contributions | $168,869,470 | AllOtherContributionsAmt |
| Noncash Contributions | $259,914 | NoncashContributionsAmt |
| Total Contributions | $305,315,221 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Desc | CONSULTANCIES | Desc |
| Business | 541900 | BusinessCd |
| Total Revenue Column | $1,500 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $1,500 | RelatedOrExemptFuncIncomeAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $1,500 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $2,963,587 | TotalRevenueColumnAmt |
| Exclusion | $2,963,587 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $78,640,623 | SecuritiesAmt |
| Other | $547,000 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $78,565,632 | SecuritiesAmt |
| Other | $548,448 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $74,991 | SecuritiesAmt |
| Other | -$1,448 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $73,543 | TotalRevenueColumnAmt |
| Exclusion | $73,543 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| OTHER | 900099 | $884,888 | $884,888 |
| REIMBURSEMENTS | 900099 | $95,672 | $95,672 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $980,560 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $309,334,411 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $1,500 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $4,017,690 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,575,733 | TotalAmt |
| Program Services | $20,575,733 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,313 | TotalAmt |
| Program Services | $9,313 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $42,177,100 | TotalAmt |
| Program Services | $42,177,100 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,260,713 | TotalAmt |
| Program Services | $309,550 | ProgramServicesAmt |
| Management And General | $3,899,884 | ManagementAndGeneralAmt |
| Fundraising | $51,279 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $102,073,963 | TotalAmt |
| Program Services | $74,628,680 | ProgramServicesAmt |
| Management And General | $26,015,749 | ManagementAndGeneralAmt |
| Fundraising | $1,429,534 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,426,617 | TotalAmt |
| Management And General | $10,426,617 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $16,197,399 | TotalAmt |
| Program Services | $1,718,558 | ProgramServicesAmt |
| Management And General | $14,478,841 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,586,983 | TotalAmt |
| Program Services | $3,707 | ProgramServicesAmt |
| Management And General | $6,583,276 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $394,432 | TotalAmt |
| Program Services | $171,093 | ProgramServicesAmt |
| Management And General | $223,097 | ManagementAndGeneralAmt |
| Fundraising | $242 | FundraisingAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $331,915 | TotalAmt |
| Program Services | $33,164 | ProgramServicesAmt |
| Management And General | $298,751 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,000 | TotalAmt |
| Program Services | $12,000 | ProgramServicesAmt |
| Management And General | $14,000 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $207,672 | TotalAmt |
| Management And General | $207,672 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $20,027,156 | TotalAmt |
| Program Services | $13,543,689 | ProgramServicesAmt |
| Management And General | $6,447,874 | ManagementAndGeneralAmt |
| Fundraising | $35,593 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $165,753 | TotalAmt |
| Program Services | $90,386 | ProgramServicesAmt |
| Management And General | $7,269 | ManagementAndGeneralAmt |
| Fundraising | $68,098 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,810,563 | TotalAmt |
| Program Services | $7,390,713 | ProgramServicesAmt |
| Management And General | $1,376,052 | ManagementAndGeneralAmt |
| Fundraising | $43,798 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $732,838 | TotalAmt |
| Program Services | $219,457 | ProgramServicesAmt |
| Management And General | $465,295 | ManagementAndGeneralAmt |
| Fundraising | $48,086 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $381,001 | TotalAmt |
| Program Services | $202,061 | ProgramServicesAmt |
| Management And General | $178,910 | ManagementAndGeneralAmt |
| Fundraising | $30 | FundraisingAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,048,542 | TotalAmt |
| Program Services | $389,297 | ProgramServicesAmt |
| Management And General | $11,659,245 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $19,986,534 | TotalAmt |
| Program Services | $18,565,722 | ProgramServicesAmt |
| Management And General | $1,358,161 | ManagementAndGeneralAmt |
| Fundraising | $62,651 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,333,110 | TotalAmt |
| Program Services | $8,022,756 | ProgramServicesAmt |
| Management And General | $269,979 | ManagementAndGeneralAmt |
| Fundraising | $40,375 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,819 | TotalAmt |
| Management And General | $8,819 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,974,173 | TotalAmt |
| Program Services | $3,101 | ProgramServicesAmt |
| Management And General | $2,971,072 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $725,361 | TotalAmt |
| Program Services | $187,114 | ProgramServicesAmt |
| Management And General | $538,247 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| SUBCONTRACTS | $24,705,297 | $23,525,529 | $1,132,123 | $47,645 |
| EQUIP RENT & MAINT | $3,443,347 | $2,203,342 | $1,236,793 | $3,212 |
| LEAVE & BENS ALLOC | $0 | $36,911,256 | -$37,679,297 | $768,041 |
| FACILITIES ALLOC | $0 | $12,623,474 | -$12,990,044 | $366,570 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,156,135 | TotalAmt |
| Program Services | $5,264,264 | ProgramServicesAmt |
| Management And General | $1,670,390 | ManagementAndGeneralAmt |
| Fundraising | $221,481 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $312,766,469 | TotalAmt |
| Program Services | $268,781,059 | ProgramServicesAmt |
| Management And General | $40,798,775 | ManagementAndGeneralAmt |
| Fundraising | $3,186,635 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,035,980 | BOYAmt |
| EOY | $7,576,050 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,493,254 | BOYAmt |
| EOY | $14,017,223 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $254,454,281 | BOYAmt |
| EOY | $35,571,476 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,578,928 | BOYAmt |
| EOY | $10,652,789 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,753,758 | BOYAmt |
| EOY | $5,307,245 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $36,534,903 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $25,486,998 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $11,878,205 | BOYAmt |
| EOY | $11,047,905 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $176,133,425 | BOYAmt |
| EOY | $153,328,545 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $619,867 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $467,947,698 | BOYAmt |
| EOY | $237,501,233 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $50,220,817 | BOYAmt |
| EOY | $202,736,996 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $576,675 | BOYAmt |
| EOY | $194,878 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $50,797,492 | BOYAmt |
| EOY | $202,931,874 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $25,292,293 | BOYAmt |
| EOY | $19,811,400 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $388,460,737 | BOYAmt |
| EOY | $14,757,959 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,397,176 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $417,150,206 | BOYAmt |
| EOY | $34,569,359 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $467,947,698 | BOYAmt |
| EOY | $237,501,233 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part XI | Yes (X) | InfoInScheduleOPartXIInd |
| Reconcilation Revenue Expnss | -$3,432,058 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$393,146 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | -$378,755,643 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $286,891,535 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $243,499,792 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $298,315,988 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $347,844,394 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $305,316,107 | CurrentTaxYearAmt |
| Total | $1,481,867,816 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $286,891,535 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $243,499,792 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $298,315,988 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $347,844,394 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $305,316,107 | CurrentTaxYearAmt |
| Total | $1,481,867,816 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $647,466,981 | SubstantialContributorsTotAmt |
| Public Support Total170 | $834,400,835 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,370,599 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $1,471,233 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $1,797,794 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $2,050,888 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $2,963,587 | CurrentTaxYearAmt |
| Total | $9,654,101 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $38,502 | CurrentTaxYearMinus4YearsAmt |
| Total | $38,502 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $763,131 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,551,502 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $4,668,393 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $5,225,302 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $980,560 | CurrentTaxYearAmt |
| Total | $14,188,888 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,505,749,307 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $250,697 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.55410 | PublicSupportCY170Pct |
| Public Support PY170 | 0.59120 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $7,856 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $217,088 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $224,944 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $311,815,894 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $312,040,838 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $156,961 | CurrentYearMinus3Amt |
| Current Year Minus2 | $168,991 | CurrentYearMinus2Amt |
| Current Year Minus1 | $294,096 | CurrentYearMinus1Amt |
| Current Year | $224,944 | CurrentYearAmt |
| Total | $844,992 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $14,461 | CurrentYearMinus3Amt |
| Current Year Minus2 | $470 | CurrentYearMinus2Amt |
| Current Year Minus1 | $127,336 | CurrentYearMinus1Amt |
| Current Year | $7,856 | CurrentYearAmt |
| Total | $150,123 | TotalAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,056,545 | BeginningYearBalanceAmt |
| Contributions | $1,240 | ContributionsAmt |
| Investment Earnings Or Losses | -$494,491 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $467,377 | OtherExpendituresAmt |
| End Year Balance | $9,095,917 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,339,249 | BeginningYearBalanceAmt |
| Contributions | $3,410 | ContributionsAmt |
| Investment Earnings Or Losses | $1,159,282 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $445,396 | OtherExpendituresAmt |
| End Year Balance | $10,056,545 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $8,897,224 | BeginningYearBalanceAmt |
| Contributions | $4,256 | ContributionsAmt |
| Investment Earnings Or Losses | $907,978 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $470,209 | OtherExpendituresAmt |
| End Year Balance | $9,339,249 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,404,188 | BeginningYearBalanceAmt |
| Contributions | $2,665 | ContributionsAmt |
| Investment Earnings Or Losses | -$58,783 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $450,846 | OtherExpendituresAmt |
| End Year Balance | $8,897,224 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,016,994 | BeginningYearBalanceAmt |
| Contributions | $9,350 | ContributionsAmt |
| Investment Earnings Or Losses | $768,184 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $390,340 | OtherExpendituresAmt |
| End Year Balance | $9,404,188 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.36000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.37000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.27000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $20,479,518 | OtherCostOrOtherBasisAmt |
| Depreciation | $13,086,483 | DepreciationAmt |
| Book Value | $7,393,035 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,835,427 | OtherCostOrOtherBasisAmt |
| Depreciation | $8,231,189 | DepreciationAmt |
| Book Value | $2,604,238 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,219,958 | OtherCostOrOtherBasisAmt |
| Depreciation | $4,169,326 | DepreciationAmt |
| Book Value | $1,050,632 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $11,047,905 | TotalBookValueLandBuildingsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART V, LINE 4: | FormAndLineReferenceDesc |
| Explanation | IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY, PATH UTILIZES THE INCOME EARNED ON THE ENDOWMENT FUNDS AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (45 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $14,826 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $979 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | GRANTMAKING | $380,632 | |
| EAST ASIA AND THE PACIFIC | 4 | 89 | MANAGEMENT & GENERAL | $1,040,096 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $4,441,155 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $310,893 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $79,330 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | OTHER | $2,940 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | FUNDRAISING | $68,916 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $4,746,774 | |
| EUROPE | 1 | 6 | MANAGEMENT & GENERAL | $20,005 | |
| EUROPE | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $1,565,902 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $4,020,990 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $205,993 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | OTHER | $3,105 |
| EUROPE | 0 | 0 | FUNDRAISING | $11,452 | |
| EUROPE | 0 | 0 | GRANTMAKING | $23,522,629 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $218 |
| NORTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | $56,482 | |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $121,949 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $194,221 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $44,284 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $733,350 | |
| RUSSIA AND NEIGHBORING STATES | 1 | 24 | MANAGEMENT & GENERAL | $295,153 | |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $2,753,844 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | GRANTMAKING | $1,133,768 | |
| SOUTH AMERICA | 1 | 3 | MANAGEMENT & GENERAL | $48,946 | |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $402,511 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $2,836 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $3,228 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | OTHER | $34 |
| SOUTH AMERICA | 0 | 0 | GRANTMAKING | $138,891 | |
| SOUTH ASIA | 4 | 91 | MANAGEMENT & GENERAL | $1,420,932 | |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $3,526,336 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $493,818 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $617,215 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | OTHER | $11,038 |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $1,886,168 | |
| SUB-SAHARAN AFRICA | 36 | 817 | MANAGEMENT & GENERAL | $10,173,517 | |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $54,325,843 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $1,037,175 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $1,003,695 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | OTHER | $1,581,091 |
| SUB-SAHARAN AFRICA | 0 | 0 | FUNDRAISING | $12,972 | |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $9,634,888 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 4 | SubtotalOfficesCnt |
| Subtotal Employees | 89 | SubtotalEmployeesCnt |
| Continuation Total Office | 43 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 941 | ContinuationTotalEmployeeCnt |
| Total Office | 47 | TotalOfficeCnt |
| Total Employee | 1030 | TotalEmployeeCnt |
| Subtotal Spent | $6,270,851 | SubtotalSpentAmt |
| Continuation Spent | $125,820,169 | ContinuationSpentAmt |
| Total Spent | $132,091,020 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (183 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| CENTRAL AMERICA & THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $150,305 | CHECK/WIRE |
| CENTRAL AMERICA & THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $230,327 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $5,056 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $5,855 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $6,014 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $6,316 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $6,683 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $7,428 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $7,496 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $8,651 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $8,726 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $8,831 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $17,290 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $18,465 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $18,988 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $20,165 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $20,651 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $30,000 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $36,845 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE | $41,922 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $51,551 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $52,029 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $54,779 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $63,761 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $72,805 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $88,594 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $100,267 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $124,235 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $174,483 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $210,000 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | GLOBAL HEALTH PROGRAMS | $340,199 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $906,750 | CHECK/WIRE |
| EAST ASIA & THE PACIFIC | ESSENTIAL MEDICINE | $2,220,200 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $5,487 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $15,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $20,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $42,190 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $47,584 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $91,299 | CHECK/WIRE |
| EUROPE | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $95,018 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $100,000 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $110,493 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $125,000 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $184,850 | CHECK/WIRE |
| EUROPE | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $258,278 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $260,000 | CHECK/WIRE |
| EUROPE | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $330,632 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $331,139 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $350,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE | $672,105 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $858,186 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $1,127,499 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $1,636,289 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $13,537,059 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS, ESSENTIAL MEDICINE, TECHNOLOGY, ANALYTICS AND MARKET INNOVATION, AND OTHER | $3,321,058 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $38,669 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $133,260 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $561,421 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $15,822 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $17,708 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $17,925 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $21,417 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $23,824 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $28,182 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $30,506 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $33,192 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $36,049 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $39,440 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $40,919 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $44,199 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $55,632 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $72,476 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $89,186 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $114,306 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $115,520 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $148,673 | CHECK/WIRE |
| RUSSIA & NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $188,791 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $20,000 | CHECK/WIRE |
| SOUTH AMERICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $32,890 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $86,001 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $5,524 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $10,449 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $15,000 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $23,210 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $40,450 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $54,148 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $70,000 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $76,827 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $85,762 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $189,652 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $300,000 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $461,944 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $553,203 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,044 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,663 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,731 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $7,853 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $10,474 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $10,577 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $10,653 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $10,742 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $11,068 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $11,364 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,207 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $12,240 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,567 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $12,698 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,773 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,336 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,567 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,740 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,937 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $14,232 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,345 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,403 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,423 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,444 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,548 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,596 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,786 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,828 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,913 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $14,941 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $15,024 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $15,232 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $15,475 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $15,706 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $17,894 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $19,200 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $20,424 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $20,918 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $21,623 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $21,769 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $22,301 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $23,061 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $23,327 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $24,586 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $24,953 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $25,222 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $27,010 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $27,314 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $27,323 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $28,097 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $28,185 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $28,842 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $29,409 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $29,615 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $30,553 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $33,176 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $37,570 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $37,612 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $38,771 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $39,283 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $42,015 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $42,522 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $42,821 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $45,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $45,005 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $49,896 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $50,367 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $51,041 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $51,721 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $53,203 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $53,323 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $61,616 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $70,705 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE | $86,825 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $90,313 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $92,565 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $94,051 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $94,299 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $109,395 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $116,943 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $136,668 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $143,568 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $154,101 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $199,361 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $289,929 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $328,475 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $372,808 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $386,133 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $1,520,852 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $3,632,614 | CHECK/WIRE |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 132 | Total501c3OrgCnt |
| Total Other Org | 50 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (66 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| GLOBAL HEALTH CORPS | ||||||||
| 318 WEST 39TH STREET ROOM 9L | NEW YORK | NY | 10018 | 800512336 | 501(C)(3) | $6,456 | GLOBAL HEALTH PROGRAMS | |
| MANAGEMENT SCIENCES FOR HEALTH | ||||||||
| 200 RIVERS EDGE DRIVE SUITE 320 | MEDFORD | MA | 02155 | 042482188 | 501(C)(3) | $9,967 | GLOBAL HEALTH PROGRAMS | |
| VAYU INC | ||||||||
| 847 WILLOW RUN AIRPORT DR | YPSILANTI | MI | 48198 | 465737909 | N/A | $10,000 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| JHPIEGO | ||||||||
| 1615 THAMES STREET SUITE 200 | BALTIMORE | MD | 212313447 | 237424444 | 501(C)(3) | $15,000 | GLOBAL HEALTH PROGRAMS | |
| TECHCHANGE INC | ||||||||
| 2001 13TH ST NW 2ND FLOOR | WASHINGTON | DC | 20009 | 273358772 | N/A | $16,500 | GLOBAL HEALTH PROGRAMS | |
| UNIVERSITY OF MIAMI | ||||||||
| MED CAMPUS PO BOX 016960 M-859 | MIAMI | FL | 33101 | 590624458 | 501(C)(3) | $17,108 | ESSENTIAL MEDICINE | |
| UNIVERSITY OF MASSACHUSETTS | ||||||||
| MEDICAL SCHOOL 55 LAKE AVE NORTH | WORCESTER | MA | 01655 | 043167352 | GOV | $20,000 | ESSENTIAL MEDICINE | |
| BENEVOLENT HEALTHCARE FOUNDATION DBA PROJECT CURE | ||||||||
| 10377 E GEDDES AVENUE SUITE 200 | CENTENNIAL | CO | 80112 | 841568566 | 501(C)(3) | $28,597 | GLOBAL HEALTH PROGRAMS | |
| MEDICAL CARE DEVELOPMENT INC | ||||||||
| 11 PARKWOOD DRIVE | AUGUSTA | ME | 04330 | 016022787 | 501(C)(3) | $28,973 | GLOBAL HEALTH PROGRAMS | |
| ROSTROPOVICH-VISHNEVSKAYA FOUNDATION | ||||||||
| 1776 K STREET NW SUITE 700 | WASHINGTON | DC | 20006 | 521752473 | 501(C)(3) | $29,244 | ESSENTIAL MEDICINE | |
| UNIVERSITY OF SOUTH FLORIDA | ||||||||
| 4202 EAST FOWLER AVENUE ALN 147 | TAMPA | FL | 33620 | 593102112 | GOV | $29,628 | ESSENTIAL MEDICINE | |
| AMREF HEALTH AFRICA INC | ||||||||
| 4 WEST 43RD STREET 2ND FLOOR | NEW YORK | NY | 10036 | 131867411 | 501(C)(3) | $33,772 | GLOBAL HEALTH PROGRAMS | |
| SEATTLE CHILDREN'S HOSPITAL | ||||||||
| PO BOX 5371 M/S RC-507 | SEATTLE | WA | 981455005 | 910564748 | 501(C)(3) | $39,739 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| THE WILLIAM DAVIDSON INST AT THE UNIV OF MICHIGAN (WDI) | ||||||||
| 724 E UNIVERSITY AVE WYLY HALL | ANN ARBOR | MI | 48109 | 383048086 | 501(C)(3) | $42,923 | GLOBAL HEALTH PROGRAMS | FIRST FLOOR |
| PARSYL INC | ||||||||
| 3963 WALNUT STREET STE 200 | DENVER | CO | 80205 | 814027966 | N/A | $46,400 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| CARDNO EMERGING MARKETS | ||||||||
| 2107 WILSON BLVD STE 800 | ARLINGTON | VA | 22201 | 521788060 | N/A | $57,894 | GLOBAL HEALTH PROGRAMS | |
| POPULATION SERVICES INT'L INC | ||||||||
| 1120 19TH ST NW STE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $59,381 | GLOBAL HEALTH PROGRAMS | |
| GHP SOLUTIONS LLC | ||||||||
| 220 EAST 42ND STREET SUITE 710 | NEW YORK | NY | 10017 | 061652595 | N/A | $61,474 | GLOBAL HEALTH PROGRAMS | |
| SOLAR ELECTRIC LIGHT FUND | ||||||||
| 1612 K STREET NW SUITE 300 | WASHINGTON | DC | 20006 | 521701564 | 501(C)(3) | $66,402 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| PAN AMERICAN HEALTH ORGANIZATION | ||||||||
| 525 23RD STREET NW | WASHINGTON | DC | 20037 | 237072046 | 501(C)(3) | $67,799 | GLOBAL HEALTH PROGRAMS | |
| UNIVERSITY OF MARYLAND | ||||||||
| PO BOX 41428 | BALTIMORE | MD | 212036428 | 526002033 | 501(C)(3) | $69,971 | ESSENTIAL MEDICINE | |
| THE UNIVERSITY OF TEXAS AT AUSTIN | ||||||||
| 110 INNER CAMPUS DRIVE STOP K5300 | AUSTIN | TX | 78712 | 746000203 | GOV | $80,000 | ESSENTIAL MEDICINE | |
| OPENMRS INC | ||||||||
| 10425 COMMERCE DR STE 110 | CARMEL | IN | 460327643 | 455316647 | 501(C)(3) | $88,500 | GLOBAL HEALTH PROGRAMS | |
| HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC | ||||||||
| 6720-A ROCKLEDGE DRIVE STE 100 | BETHESDA | MD | 20817 | 521317896 | 501(C)(3) | $89,999 | ESSENTIAL MEDICINE | |
| BASIC HEALTH INTERNATIONAL INC | ||||||||
| 25 BROADWAY 10TH FLOOR | NEW YORK | NY | 10004 | 203408717 | 501(C)(3) | $93,074 | GLOBAL HEALTH PROGRAMS | |
| THE ALBERT B SABIN VACCINE INSTITUTE INC | ||||||||
| 2175 K STREET NW SUITE 400 | WASHINGTON | DC | 20037 | 061389829 | 501(C)(3) | $100,000 | ESSENTIAL MEDICINE | |
| FOOD AND DRUG ADMINISTRATION | ||||||||
| 5600 FISHERS LN HFA-140 RM 11-40 | ROCKVILLE | MD | 20857 | 530196965 | GOV | $110,500 | ESSENTIAL MEDICINE | |
| HEALTH ALLIANCE INTERNATIONAL | ||||||||
| 4534 11TH AVENUE NE | SEATTLE | WA | 98105 | 943047981 | 501(C)(3) | $118,329 | GLOBAL HEALTH PROGRAMS | |
| QUALIS HEALTH | ||||||||
| 10700 MERIDIAN AVE N SUITE 100 | SEATTLE | WA | 98133 | 911072875 | 501(C)(3) | $127,144 | GLOBAL HEALTH PROGRAMS | |
| KYBELE INC | ||||||||
| 3524 YADKINVILLE ROAD 124 | WINSTONSALEM | NC | 27106 | 900759003 | 501(C)(3) | $133,219 | GLOBAL HEALTH PROGRAMS | |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 501(C)(3) | $140,000 | ESSENTIAL MEDICINE | |
| UNIVERSITY OF VERMONT AND STATE | ||||||||
| AGRICULTURAL COLLEGE 85 SOUTH | BURLINGTON | VT | 05405 | 030179440 | 501(C)(3) | $141,493 | ESSENTIAL MEDICINE | PROSPECT STREET |
| ACESO GLOBAL | ||||||||
| 1400 16TH STREET NW SUITE 430 | WASHINGTON | DC | 20036 | 474215911 | 501(C)(3) | $145,548 | GLOBAL HEALTH PROGRAMS | |
| HJF MEDICAL RESEARCH INTERNATIONAL INC | ||||||||
| 6720A ROCKLEDGE DRIVE SUITE 100 | BETHESDA | MD | 20817 | 522322791 | 501(C)(3) | $136,117 | GLOBAL HEALTH PROGRAMS | |
| HEIFER INTERNATIONAL DC | ||||||||
| 1 WORLD AVENUE | LITTLE ROCK | AR | 72202 | 351019477 | 501(C)(3) | $158,702 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| ED ZERO EMERSON PL 104 | BOSTON | MA | 02114 | 041564655 | 501(C)(3) | $175,000 | ESSENTIAL MEDICINE | |
| ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION | ||||||||
| AIDS FOUNDATION 1140 CONNECTICUT | WASHINGTON | DC | 20036 | 954191698 | 501(C)(3) | $223,762 | GLOBAL HEALTH PROGRAMS | AQG NW 200 |
| SEATTLE BIOMEDICAL RESEARCH INSTITUTE | ||||||||
| INSTITUTE 307 WESTLAKE AVE N SUITE | SEATTLE | WA | 981095219 | 910961784 | 501(C)(3) | $226,438 | ESSENTIAL MEDICINE | 500 |
| HARVARD UNIVERSITY | ||||||||
| 1033 MASSACHUSETTS AVE 2ND FLOOR | CAMBRIDGE | MA | 02115 | 042103580 | 501(C)(3) | $233,379 | GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE | |
| TULANE UNIVERSITY | ||||||||
| 6823 ST CHARLES AQGE | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $235,475 | GLOBAL HEALTH PROGRAMS | |
| THE STATE UNIVERSITY OF NEW ANORK | ||||||||
| 35 STATE STREET | ALBANY | NY | 122072826 | 141368361 | 501(C)(3) | $292,383 | ESSENTIAL MEDICINE | |
| BRIGHAM & WOMEN'S HOSPITAL INC | ||||||||
| 651 HUNTINGTON AVE FXB BUILDING | BOSTON | MA | 02115 | 042312909 | 501(C)(3) | $302,658 | GLOBAL HEALTH PROGRAMS | |
| CASCADE DESIGNS INC | ||||||||
| 4000 1ST AVE SOUTH | SEATTLE | WA | 98134 | 910969695 | N/A | $315,000 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| FINA BIOSOLUTIONS LLC | ||||||||
| 9430 KEY WEST AVE SUITE 200 | ROCKVILLE | MD | 20850 | 205448275 | N/A | $321,231 | ESSENTIAL MEDICINE | |
| HARVARD SCHOOL OF PUBLIC HEALTH | ||||||||
| 677 HUNTINGTON AVENUE | BOSTON | MA | 02215 | 042103580 | 501(C)(3) | $374,803 | ESSENTIAL MEDICINE | |
| DUKE UNIVERSITY | ||||||||
| BOX 104132 | DURHAM | NC | 27708 | 560532129 | 501(C)(3) | $397,629 | ESSENTIAL MEDICINE | |
| INITIATIVES INC | ||||||||
| 264 BEACON STREET | BOSTON | MA | 02116 | 042961350 | N/A | $399,082 | GLOBAL HEALTH PROGRAMS | |
| CINCINNATI CHILDREN'S HOSPITAL | ||||||||
| MEDICAL CENTER 3333 BURNET AVE ML | CINCINNATI | OH | 452293039 | 310833936 | 501(C)(3) | $415,954 | ESSENTIAL MEDICINE | 6014 |
| US NAVAL MEDICAL RESEARCH | ||||||||
| UNIT NO 3 NAMRU-3 503 ROBERT GRANT | SILVER SPRING | MD | 20901 | 470100048 | GOV | $434,441 | ESSENTIAL MEDICINE | AVE BLDG500 |
| RESULTS FOR DEVELOPMENT INSTITUTE INC | ||||||||
| 1100 15TH STREET NW SUITE 400 | WASHINGTON | DC | 20005 | 208530747 | 501(C)(3) | $452,200 | GLOBAL HEALTH PROGRAMS | |
| EHEALTH AFRICA | ||||||||
| 1200 G ST NW SUITE 800 | WASHINGTON | DC | 20005 | 814503438 | 501(C)(3) | $482,335 | GLOBAL HEALTH PROGRAMS | |
| POPULATION COUNCIL | ||||||||
| ONE DAG HAMMERKJOLD PLAZA | NEW YORK | NY | 10017 | 131687001 | 501(C)(3) | $535,709 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | |
| INTRAHEALTH INTERNATIONAL INC | ||||||||
| 6340 QUADRANGLE DRIVE SUITE 200 | CHAPEL HILL | NC | 27517 | 550825466 | 501(C)(3) | $574,134 | GLOBAL HEALTH PROGRAMS | |
| SYSTMAPP INC | ||||||||
| 2000 TOWN CENTER SUITE 300 | SOUTHFIELD | MI | 48075 | 812936844 | N/A | $600,000 | GLOBAL HEALTH PROGRAMS | |
| VILLAGEREACH | ||||||||
| 2900 EASTLAKE AVE E SUITE 230 | SEATTLE | WA | 981023012 | 912088484 | 501(C)(3) | $687,045 | GLOBAL HEALTH PROGRAMS | |
| THE SCRIPPS RESEARCH INSTITUTE | ||||||||
| 10550 N TORREY PINES ROAD | LA JOLLA | CA | 92037 | 330435954 | 501(C)(3) | $756,375 | ESSENTIAL MEDICINE | |
| INVENTPRISE LLC | ||||||||
| 18133 NE 68TH STREET SUITE D 150 | REDMOND | WA | 98052 | 454927373 | N/A | $789,523 | ESSENTIAL MEDICINE | |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| BLOOMBERG SCHL OF PUB HLTH 615 N | BALTIMORE | MD | 21205 | 520595110 | 501(C)(3) | $831,856 | GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE | WOLFE STREET |
| UNIVERSITY OF WASHINGTON | ||||||||
| GRANT CONTRACT ACCOUNTING 12455 | CHICAGO | IL | 60693 | 916001537 | 501(C)(3) | $1,225,899 | GLOBAL HEALTH PROGRAMS, ESSENTIAL MEDICINE, & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | COLLECTIONS DRIVE |
| BECTON DICKINSON & COMPANY | ||||||||
| ONE BECTON DRIVE | FRANKLIN LAKES | NJ | 07417 | N/A | $1,386,791 | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | ||
| NAT'L INST OF ALLERGY & INFECTIOUS DISEASES | ||||||||
| 6610 ROCKLEDGE DR ROOM 2800 | BETHESDA | MD | 208926606 | 520858115 | GOV | $1,387,280 | ESSENTIAL MEDICINE | |
| JSI RESEARCH AND TRAINING INSTITUTE INC | ||||||||
| 1616 NORTH FORT MYER DR 16TH FLOOR | ARLINGTON | VA | 222093100 | 042679824 | N/A | $1,390,705 | GLOBAL HEALTH PROGRAMS | |
| WALTER REED ARMY INSTITUTE OF RESEARCH | ||||||||
| US TREASURY 503 ROBERT GRANT AVE | SILVER SPRING | MD | 20910 | 520664528 | GOV | $2,994,916 | ESSENTIAL MEDICINE | |
| YALE UNIVERSITY | ||||||||
| GRANT AND CONTRACT FINANCIAL ADMIN | NEW HAVEN | CT | 065081873 | 060646973 | 501(C)(3) | -$182,082 | ESSENTIAL MEDICINE | PO BOX 1873 |
| WORLD VISION | ||||||||
| PO BOX 9716 DPTW | FEDERAL WAY | WA | 980639716 | 951922279 | 501(C)(3) | -$86,473 | GLOBAL HEALTH PROGRAMS | |
| HELEN KELLER INTERNATIONAL INC | ||||||||
| 352 PARK AVENUE SOUTH FLOOR 12 | NEW YORK | NY | 10010 | 135562162 | 501(C)(3) | -$18,449 | GLOBAL HEALTH PROGRAMS | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 51 | Total501c3OrgCnt |
| Total Other Org | 12 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | GRANT | GrantTypeTxt |
| Recipient | 1 | RecipientCnt |
| Cash Grant | $9,313 | CashGrantAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (16 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEPHEN B DAVIS | ||||||||||||||
| PRESIDENT AND CEO | $512,010 | $0 | $152,067 | $0 | $1,800 | $0 | $32,200 | $0 | $30,580 | $0 | $728,657 | $0 | $0 | $0 |
| OLIVIA D POLIUS | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $318,546 | $0 | $0 | $0 | $2,100 | $0 | $32,400 | $0 | $19,536 | $0 | $372,582 | $0 | $0 | $0 |
| DANIEL LASTER | ||||||||||||||
| COO AND GENERAL COUNSEL | $308,869 | $0 | $0 | $0 | $1,800 | $0 | $32,400 | $0 | $9,144 | $0 | $352,213 | $0 | $0 | $0 |
| DAVID C KASLOW | ||||||||||||||
| VP - PRODUCT DEVELOPMENT | $377,245 | $0 | $0 | $0 | $1,800 | $0 | $32,400 | $0 | $33,278 | $0 | $444,723 | $0 | $0 | $0 |
| AMIE E BATSON | ||||||||||||||
| CHIEF STRATEGY OFFICER | $194,527 | $0 | $0 | $0 | $183,623 | $0 | $21,347 | $0 | $1,230 | $0 | $400,727 | $0 | $0 | $0 |
| KATHY CAHILL | ||||||||||||||
| VP - INTERNATIONAL DEVELOPMENT | $195,454 | $0 | $0 | $0 | $149,559 | $0 | $23,454 | $0 | $3,166 | $0 | $371,633 | $0 | $0 | $0 |
| DAVID W FLEMING | ||||||||||||||
| VP - PUBLIC HEALTH IMPACT | $286,869 | $0 | $0 | $0 | $0 | $0 | $32,400 | $0 | $18,211 | $0 | $337,480 | $0 | $0 | $0 |
| KATHRYN A O'DRISCOLL | ||||||||||||||
| CHIEF HUMAN RESOURCES OFFICER | $152,146 | $0 | $0 | $0 | $127,674 | $0 | $18,452 | $0 | $9,262 | $0 | $307,534 | $0 | $0 | $0 |
| ERICA J SESSLE | ||||||||||||||
| CHIEF OF STAFF | $212,878 | $0 | $0 | $0 | $1,500 | $0 | $23,510 | $0 | $11,224 | $0 | $249,112 | $0 | $0 | $0 |
| PRAVEEN RAJA | ||||||||||||||
| VP - TECH. DEV. & INNOVATION | $332,163 | $0 | $0 | $0 | $840 | $0 | $20,239 | $0 | $11,173 | $0 | $364,415 | $0 | $0 | $0 |
| ELAINE L GIBBONS | ||||||||||||||
| VP - GLOBAL ENGAGEMENT | $264,986 | $0 | $0 | $0 | $840 | $0 | $32,400 | $0 | $33,413 | $0 | $331,639 | $0 | $0 | $0 |
| JEFFREY D BERSON | ||||||||||||||
| ASSOCIATE DIRECTOR II | $170,197 | $0 | $0 | $0 | $261,254 | $0 | $24,555 | $0 | $57,549 | $0 | $513,555 | $0 | $0 | $0 |
| JAMES B MCKENNA | ||||||||||||||
| ASSOCIATE DIRECTOR II | $141,788 | $0 | $0 | $0 | $254,520 | $0 | $21,650 | $0 | $53,582 | $0 | $471,540 | $0 | $0 | $0 |
| TRAD M HATTON | ||||||||||||||
| CHIEF OF PARTY | $134,488 | $0 | $0 | $0 | $186,718 | $0 | $17,173 | $0 | $31,611 | $0 | $369,990 | $0 | $0 | $0 |
| BRUCE LAMONT INNIS | ||||||||||||||
| GLOBAL DISEASE AREA HEAD | $310,536 | $0 | $0 | $0 | $840 | $0 | $27,312 | $0 | -$667 | $0 | $338,021 | $0 | $0 | $0 |
| JOHN O KONZ | ||||||||||||||
| GLOBAL INT. PORT/FIN MGMT. CVIA HEAD | $298,375 | $0 | $0 | $0 | $840 | $0 | $32,400 | $0 | $32,203 | $0 | $363,818 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. |
| PART I, LINE 4A | THE FOLLOWING EMPLOYEES RECEIVED SEVERANCE PAYMENTS IN 2018: - KATHRYN A. O'DRISCOLL $126,624 - AMIE BATSON $162,501 - KATHY CAHILL $143,503 |
| PART I, LINE 7 | BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 19 | ContributionCnt |
| Noncash Contributions Rpt F990 | $242,558 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | SUPPLIES | Desc |
| Contribution | 3 | ContributionCnt |
| Noncash Contributions Rpt F990 | $17,356 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (10 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1 | PATH IS A GLOBAL ORGANIZATION THAT WORKS TO ACCELERATE HEALTH EQUITY BY BRINGING TOGETHER PUBLIC INSTITUTIONS, BUSINESSES, SOCIAL ENTERPRISES, AND INVESTORS TO SOLVE THE WORLD'S MOST PRESSING HEALTH CHALLENGES. WITH EXPERTISE IN SCIENCE, HEALTH, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES SOLUTIONS-INCLUDING VACCINES, DRUGS, DEVICES, DIAGNOSTICS, AND INNOVATIVE APPROACHES TO STRENGTHENING HEALTH SYSTEMS WORLDWIDE. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE REACHED AN AVERAGE OF MORE THAN 150 MILLION PEOPLE EACH YEAR WITH LIFESAVING HEALTH SOLUTIONS. |
| FORM 990, PART III, LINE 4A | PATH CONTINUED TO PILOT INNOVATIONS TO REACH MOST-AT-RISK POPULATIONS IN VIETNAM. WE EQUIPPED SOCIAL AND SUPPORT GROUPS OPERATED BY MEMBERS OF KEY POPULATIONS TO GENERATE DEMAND FOR SERVICES AMONG THEIR PEERS THROUGH TARGETED OUTREACH VIA SOCIAL MEDIA, LINKAGES TO HIV TESTING SERVICES THROUGH MOBILE APPLICATIONS, AND SCALE-UP OF HIV SELF-TESTING AND PREP. PATH ALSO ENGAGED THE GOVERNMENT OF VIETNAM TO INTRODUCE NEW MODELS OF HIV TESTING, INCLUDING EXPANDING ACCESS TO HIV LAY- AND SELF-TESTING AND PARTNER NOTIFICATION SERVICES, INTRODUCING AND SCALING FEE-BASED PREP, LAUNCHING THREE LOCAL CONDOM BRANDS MARKETED FOR KEY POPULATIONS, AND DEVELOPING BETTER LOW-DEAD-SPACE SYRINGES FOR PEOPLE WHO INJECT DRUGS. PATH ALSO BRINGS GLOBAL HEALTH EXPERTISE AND INNOVATIVE APPROACHES TO THE FIGHT AGAINST TB. WE WORK DIRECTLY WITH PUBLIC- AND PRIVATE-SECTOR LABORATORIES TO STRENGTHEN CAPACITY TO QUICKLY DIAGNOSE DRUG-SUSCEPTIBLE, MULTIDRUG-RESISTANT, AND EXTENSIVELY DRUG-RESISTANT TB PATIENTS. WE ALSO SUPPORT FACILITIES AND LABORATORIES WITH INFRASTRUCTURE, SUCH AS SOLAR PANELS AND COMPUTER SYSTEMS, TO RUN TB DIAGNOSTIC EQUIPMENT AND ENSURE A SUSTAINABLE PLAN FOR MAINTENANCE AND CARE. IN UKRAINE, PATH LED THE USAID-FUNDED SERVING LIFE PROJECT, WORKING TO REDUCE TB, HIV, AND HEPATITIS C TRANSMISSION IN PRE-TRIAL DETENTION CENTERS, PRISONS, POST-PRISON SETTINGS, AND THE COMMUNITY. STRATEGIES INCLUDED INCREASING CASE DETECTION, STRENGTHENING LINKAGES TO CARE, AND EMPLOYING A CASE-MANAGEMENT APPROACH TO ENSURE THAT INSTITUTIONALIZED OR COMMUNITY-BASED KEY POPULATIONS WHO HAVE TB, HIV, OR HEPATITIS C CAN COMPLETE TREATMENT. IN A RELATED EFFORT, PATH PARTNERED WITH THE MINISTRY OF JUSTICE TO ENSURE THAT ALL NEWLY INCARCERATED INDIVIDUALS ARE ROUTINELY SCREENED FOR TB UPON ENTRY, ANNUALLY, AND PRIOR TO RELEASE, AND THAT THOSE CONFIRMED WITH ACTIVE TB RECEIVE TREATMENT DURING INCARCERATION OR A REFERRAL TO A TB TREATMENT FACILITY AFTER RELEASE. UNDER THE USAID-FUNDED ERADICATE TB PROJECT IN ZAMBIA, PATH ENGAGED DIRECTLY WITH PRISON ADMINISTRATORS TO PROMOTE TB SCREENING UPON ENTRY, ANNUALLY, AND PRIOR TO RELEASE. IN TANZANIA, UNDER THE CHALLENGE TB PROJECT, PATH STRENGTHENED THE CAPACITY OF SIX CIVIL-SOCIETY ORGANIZATIONS TO PROVIDE COMMUNITY-BASED TB TREATMENT ADHERENCE SUPPORT. PATH ALSO DEVELOPED A TREATMENT ADHERENCE APP THAT SENDS TREATMENT AND APPOINTMENT REMINDERS TO PEOPLE WITH TB VIA TEXT MESSAGE. AFTER ITS LAUNCH IN SEPTEMBER 2018, MORE THAN 7,500 PEOPLE ENROLLED IN THE APP. IN ADDITION, PATH DEVELOPED AND LAUNCHED A SELF-SCREENING APP TO RAISE AWARENESS ABOUT TB AND INCREASE TB CASE DETECTION. THOSE WHO SELF-REPORT AS PRESUMPTIVE FOR TB RECEIVE REFERRAL MESSAGES TO GO TO A NEARBY HEALTH FACILITY FOR CONFIRMATORY TESTING. IN INDIA, WE CONTINUED TO IMPLEMENT THE PUBLIC-PRIVATE INTERFACE AGENCY (PPIA) PROJECT TO IMPROVE PRIVATE HEALTH CARE PROVIDERS' CONTRIBUTIONS TO TB CONTROL ACROSS 15 WARDS IN THE URBAN SLUMS OF MUMBAI. IN 2018, THE PROJECT FURTHER ENGAGED WITH FORMAL AND INFORMAL PRACTITIONERS, LABORATORIES, CHEMISTS, AND HOSPITALS TO PROVIDE STANDARDIZED TB DIAGNOSIS AND TREATMENT SERVICES. PATH ALSO SUPPORTED A VOUCHER MECHANISM TO CONNECT PATIENTS FROM LOCAL INFORMAL PROVIDERS TO QUALIFIED PHYSICIANS, DIAGNOSTIC SERVICES, AND TREATMENT SUPPORT. THE PROJECT HAS DRAMATICALLY IMPROVED ACCESS TO TB SERVICES. THE BREATH FOR LIFE PROJECT IN VIETNAM DEVELOPED AND TESTED A MODEL THAT ADDRESSES HEALTH SYSTEM CHALLENGES CONTRIBUTING TO LOW DETECTION OF TB AMONG CHILDREN. OUR EFFORTS THROUGH THIS PROJECT RESULTED IN DECENTRALIZED PEDIATRIC TB DIAGNOSIS AND TREATMENT, A DOUBLING OF TB DIAGNOSIS AMONG CHILDREN, AND A FOURFOLD INCREASE IN ELIGIBLE CHILDREN ON TB PREVENTIVE THERAPY. BUILDING ON OUR PEDIATRIC WORK UNDER BREATH FOR LIFE, PATH COORDINATED WITH THE ZAMBIA MINISTRY OF HEALTH IN 2018 TO FINALIZE CHILDHOOD TB TRAINING MATERIALS. MEASUREMENT AND LEARNING CONTINUED TO SERVE AS CORNERSTONES FOR PATH'S TB PROGRAMMING. UNDER THE ERADICATE TB PROJECT IN ZAMBIA, PATH COORDINATED WITH THE MINISTRY OF HEALTH AND NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAM TO UPDATE THEIR MONITORING SYSTEMS, INCLUDING SECONDING A MONITORING AND EVALUATION (M&E) ADVISOR WHO PROVIDES ON-SITE MENTORSHIP TO NATIONAL-LEVEL GOVERNMENT OFFICIALS TO ANALYZE DATA FOR PROGRAMMATIC DECISION-MAKING. IN INDIA, PATH DEVELOPED M&E AND REPORTING GUIDELINES FOR PUBLIC-PRIVATE MIX NETWORKS AND PROVIDED DIRECT TECHNICAL ASSISTANCE TO THE GOVERNMENT TO STRENGTHEN CAPACITY IN DATA ANALYSIS AND USE. IN VIETNAM, PATH HELPED THE MINISTRY OF HEALTH TO INTEGRATE PUBLIC-PRIVATE MIX AND PEDIATRIC TB DATA-CAPTURE INTO NATIONAL M&E SYSTEMS. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION PATH WORKS WITH PARTNERS TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION AROUND THE WORLD. TOGETHER WE DEVELOP, ADAPT, AND SCALE TECHNOLOGIES AND APPROACHES TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN ALL OUR EFFORTS, WE PUT THE LOCAL GOVERNMENT IN THE DRIVER'S SEAT TO ENSURE BOTH SCALE AND SUSTAINABILITY. IN 2018, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). WITH PATH'S SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, MOZAMBIQUE, AND ZAMBIA INCORPORATED ECD SERVICES INTO BASIC HEALTH CARE FOR CAREGIVERS AND YOUNG CHILDREN. ALONG WITH WHO, UNICEF, THE WORLD BANK, AND OTHERS, PATH ALSO CONTRIBUTED TO THE DEVELOPMENT, LAUNCH, AND INTRODUCTION OF THE NURTURING CARE FOR ECD FRAMEWORK, WHICH SETS THE STRUCTURE FOR COUNTRIES TO ADOPT, ADAPT, AND SCALE ECD SERVICES. PATH'S PIONEERING WORK TO INTEGRATE ECD INTO HEALTH SYSTEMS HAS FOCUSED ON BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE SUPPORTING AND BUILDING THE CAPACITY OF EXISTING HEALTH SERVICE SYSTEMS AND PROVIDERS AT BOTH THE FACILITY AND COMMUNITY LEVELS AND STRENGTHENING REFERRAL SYSTEMS. PATH ALSO CONTINUED EFFORTS TO ENSURE THAT ALL INFANTS RECEIVE HUMAN MILK. OUR EFFORTS CENTER AROUND AN INTEGRATED MODEL FOR BREASTFEEDING PROMOTION, INCLUDING THE PROVISION OF SAFE DONOR MILK THROUGH HUMAN MILK BANKS. PATH DEVELOPED STRENGTHENING HUMAN MILK BANKING: A RESOURCE TOOLKIT FOR ESTABLISHING AND OPERATING HUMAN MILK BANK PROGRAMS, THE FIRST-EVER STANDARD TO ENSURE QUALITY AND SAFETY. PATH CONTINUED TO ADVOCATE FOR POLICIES TO GUIDE APPROPRIATE AND ETHICAL USE OF DONOR HUMAN MILK, WORKING WITH GLOBAL TECHNICAL AND POLICY LEADERS TO DRIVE SCALE-UP. PATH WORKED WITH THE KENYA MINISTRY OF HEALTH TO PREPARE FOR THE LAUNCH OF THE FIRST HUMAN MILK BANK IN THE EAST AFRICAN REGION. IN GHANA, THE MAKING EVERY BABY COUNT INITIATIVE STRENGTHENS LEADERSHIP AND CAPACITY AT THE NATIONAL AND LOCAL LEVELS TO MANAGE AND SUSTAIN BEST PRACTICES IN NEWBORN CARE. IN 2018, PATH SUPPORTED GHANA'S CENTRAL GOVERNMENT AND REGIONS TO REDUCE NEONATAL MORTALITY THROUGH SPECIFIC ACTIVITIES THAT IMPROVED AND STANDARDIZED NEWBORN CARE. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM CONTINUED TO DRIVE NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. WE ENGAGED STAKEHOLDERS WITH EXPERTISE SPANNING GLOBAL HEALTH, DEVELOPMENT, AND THE ENVIRONMENT, FROM BOTH THE PUBLIC AND PRIVATE SECTORS. IN ADDITION, PATH CONTINUED TO SUPPORT A PROJECT KNOWN AS MAXIMIZING THE QUALITY OF SCALING UP NUTRITION PLUS (MQSUN+). IN THIS PROJECT, PATH LEADS A CONSORTIUM OF FIVE ORGANIZATIONS THAT ARE EXPANDING THE EVIDENCE BASE ON THE CAUSES OF UNDERNUTRITION, ENHANCING THE SKILLS AND CAPACITY OF PARTICIPATING GOVERNMENTS TO SCALE UP NUTRITION-RELATED PROGRAMS AND POLICIES, AND PROVIDING TECHNICAL GUIDANCE ON PROGRAM DESIGN, IMPLEMENTATION, AND M&E. OTHER NUTRITION-RELATED ACTIVITIES IN 2018 INCLUDED COLLABORATION WITH THE NATURE CONSERVANCY, DUKE UNIVERSITY, AND THE INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE TO ADVANCE THE USE OF ALTERNATIVE PROTEINS; THIS WORK WAS FUNDED BY THE ROCKEFELLER FOUNDATION. IN INDIA, WE EXPANDED OUR FORTIFIED RICE SCHOOL FEEDING PROGRAM IN KARNATAKA AND GUJARAT STATES. WE CONTINUED TO DRIVE MULTISECTORAL COLLABORATION IN 2018 BY FURTHERING THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT TO ENGAGE MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. WE PUBLISHED SEVERAL PEER-REVIEWED PAPERS AND HELD SEVERAL HIGH-LEVEL MEETINGS ON THE INTERSECTION OF HUMAN AND PLANETARY HEALTH IN CONJUNCTION WITH THE UNITED NATIONS DEVELOPMENT PROGRAM. IN 2018, SEVERAL PATH STAFF MEMBERS PRESENTED AT KEY GLOBAL AND NATIONAL MEETINGS, EMPHASIZING OUR GLOBAL THOUGHT-LEADERSHIP. PATH STAFF ALSO AUTHORED, EDITED, AND CONTRIBUTED TO VARIOUS HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO DEEPLY CHALLENGING MATERNAL, |
| FORM 990, PART III, LINE 4A | NEWBORN, AND CHILD HEALTH AND NUTRITION PROBLEMS. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH IS GUIDED BY THE KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL WOMEN. BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS WOMEN'S DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS. PATH CONTINUES TO CHAMPION THE RIGHT OF WOMEN TO MANAGE THEIR OWN SEXUAL AND REPRODUCTIVE HEALTH NEEDS BY CREATING AND ADVANCING IMPROVED TOOLS AND PRACTICES THAT MAKE WOMEN'S SELF-CARE POSSIBLE. AN INTEGRATED APPROACH TO WOMEN'S HEALTH INCLUDES ATTENTION TO CONTRACEPTION, CERVICAL AND BREAST CANCER, SEXUALLY TRANSMITTED INFECTIONS, THE RIGHT TO DECIDE WHETHER AND WHEN TO BECOME A MOTHER, AND GENDER-BASED VIOLENCE PREVENTION AND CARE SERVICES. WE SPEARHEAD DISCUSSIONS ON THE PRACTICES, BEHAVIORS, AND TOOLS THAT ENABLE WOMEN TO SELF-ASSESS AND SELF-MANAGE THEIR SEXUAL AND REPRODUCTIVE HEALTH NEEDS. AMONG THE RECENT WOMAN-INITIATED PRODUCTS INTRODUCED BY PATH ARE AN ALL-IN-ONE INJECTABLE CONTRACEPTIVE THAT CAN BE SELF-ADMINISTERED AND A VAGINAL SELF-SAMPLING KIT FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN CERVICAL CANCER SCREENING PROGRAMS, AS DESCRIBED BELOW. PATH'S RESEARCH AND COORDINATION TO EXPAND ACCESS TO THE INJECTABLE CONTRACEPTIVE SUBCUTANEOUS DMPA (DMPA-SC, OR SAYANA PRESS) CONTINUED IN 2018, PRIMARILY THROUGH THE SELF-INJECTION BEST PRACTICES AND ACCESS COLLABORATIVE PROJECTS. THE SELF-INJECTION PROJECT IN UGANDA LAUNCHED TO GATHER INFORMATION ABOUT HOW THE PRACTICE CAN BE DESIGNED AND IMPLEMENTED AT SCALE. BY THE END OF 2018, AT LEAST 7,000 WOMEN WERE SELF-INJECTING ACROSS FOUR DISTRICTS THROUGH THIS PROGRAM. THE DMPA-SC ACCESS COLLABORATIVE WORKS WITH MINISTRIES OF HEALTH AND PARTNERS ACROSS SECTORS IN TEN COUNTRIES TO FACILITATE DMPA-SC COUNTRY INTRODUCTION AND SCALE-UP PLANNING FOR A RANGE OF CONTRACEPTIVE OPTIONS. IN 2018, THE COLLABORATIVE PROVIDED TECHNICAL ASSISTANCE TO ENSURE IMPLEMENTATION OF EACH COUNTRY'S TOTAL MARKET PLAN. FURTHERMORE, THE COLLABORATIVE FACILITATED LEARNING ACROSS COUNTRIES BY EXCHANGING INFORMATION, RESULTS, AND LESSONS LEARNED; TROUBLESHOOTING CHALLENGES; AND ACCELERATING THE ADOPTION OF BEST PRACTICES. PATH ALSO WORKED WITH PARTNERS WORLDWIDE AND IN SEVERAL COUNTRIES TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL PRECANCER, WHICH IS CAUSED BY INFECTION WITH HPV. WE CONTINUED OUR PARTNERSHIP WITH THE MINISTRIES OF HEALTH IN GUATEMALA, HONDURAS, AND NICARAGUA TO SUPPORT THE SCALE-UP OF HPV TESTING IN THE PUBLIC-SECTOR HEALTH SYSTEM. WE PROVIDED TECHNICAL SUPPORT FOR PROCUREMENT OF TESTS, SUPPORTED ADVOCACY AND DISSEMINATION EVENTS AT THE MINISTRIES OF HEALTH, AND MADE PROGRESS TOWARD TRANSITIONING LEADERSHIP OF THE PROGRAM TO THE MINISTRIES THEMSELVES AS THE PROJECT BEGAN ITS FINAL YEAR. WE DEDICATED ADDITIONAL EFFORTS TO EVALUATING FOLLOW-UP AND TREATMENT STRATEGIES TO ENSURE WOMEN RECEIVE APPROPRIATE CARE DURING EACH STAGE OF A COMPREHENSIVE CERVICAL CANCER PREVENTION PROGRAM. IN MYANMAR, WE ENGAGED WITH THE MINISTRY OF HEALTH AND OTHER STAKEHOLDERS TO DESIGN AN OPERATIONAL PLAN FOR CERVICAL CANCER CONTROL. PATH EXPERTS ALSO PARTICIPATED ACTIVELY IN WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION BY ATTENDING INTERNATIONAL MEETINGS TO DEFINE ELIMINATION TARGETS AND SHAPE STRATEGIES FOR LOW- AND MIDDLE-INCOME COUNTRIES. TO COMBAT BREAST CANCER, WE WORKED WITH THE NATIONAL CANCER INSTITUTE IN PERU AND OTHER REGIONAL STAKEHOLDERS TO IMPLEMENT A MODEL FOR EARLY DETECTION OF BREAST CANCER THAT IS APPROPRIATE AND FEASIBLE FOR LOW- AND MIDDLE-RESOURCE SETTINGS. WE BUILT THE CAPACITY OF NUMEROUS HEALTH PROFESSIONALS TO IMPLEMENT THIS MODEL AND CONDUCTED ADVOCACY ACTIVITIES AMONG HEALTH OFFICIALS TO ENSURE BREAST CANCER STAYS ON THE AGENDA AND WOMEN RECEIVE SCREENING AND TREATMENT EVEN IN THE ABSENCE OF MAMMOGRAPHY SERVICES. PATH ALSO CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION. THIS IS A GLOBAL PARTNERSHIP OF MORE THAN 400 PUBLIC, PRIVATE, AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO SUPPLIES, SERVICES, AND OPTIONS FOR PREVENTING UNINTENDED PREGNANCY AND SEXUALLY TRANSMITTED INFECTIONS. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT IN LOW- AND MIDDLE-INCOME COUNTRIES AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES, CARDIOVASCULAR DISEASE, AND WOMEN'S CANCERS. THESE DISEASES ARE RESPONSIBLE FOR TWO-THIRDS OF DEATHS WORLDWIDE, AND ALMOST 75 PERCENT OF THESE DEATHS OCCUR IN LOWER-RESOURCE SETTINGS. IN 2018, PATH CONTINUED TO EXPAND OUR NCD PROGRAM. THROUGH THIS PROGRAM, PATH SERVES AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES & PRODUCTS, WHICH WAS LAUNCHED IN 2017. THIS GLOBAL, MULTISECTORAL COALITION IS DEDICATED TO INCREASING ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES. MEMBERS INCLUDE GOVERNMENT AGENCIES, PRIVATE-SECTOR ENTITIES, NONGOVERNMENTAL ORGANIZATIONS, PHILANTHROPIC FOUNDATIONS, AND ACADEMIC INSTITUTIONS. IN ADDITION TO ITS GLOBAL ADVOCACY EFFORTS, THE COALITION BEGAN IMPLEMENTATION ACTIVITIES IN EAST AFRICA, STARTING WITH KENYA AND UGANDA, FOCUSING ON SUPPLY CHAIN STRENGTHENING, LANDSCAPING, AND A COSTING STUDY. IN KENYA, PATH CONTINUED TO IMPLEMENT A FIRST-OF-ITS-KIND PROGRAM THAT INTEGRATES SCREENING AND CARE FOR HYPERTENSION INTO HIV/AIDS SERVICES. THE PROGRAM WAS IN FULL IMPLEMENTATION IN 2018, WITH 51 PARTICIPATING FACILITIES. FURTHERMORE, IN PARTNERSHIP WITH KENYA'S MINISTRY OF HEALTH, PATH LAUNCHED THE NCD NAVIGATOR (PREVIOUSLY CALLED THE GLOBAL ASSESSMENT FRAMEWORK) TO MAP NCD INITIATIVES IN KENYA AND INFORM STRATEGIC PLANNING EFFORTS, IDENTIFY GAPS AND AREAS OF OVERLAP, AND SUPPORT GREATER ALIGNMENT WITH THE NATIONAL STRATEGY. IN SENEGAL, IN COLLABORATION WITH INTRAHEALTH AND THE MINISTRY OF HEALTH AND SOCIAL ACTION, PATH IMPLEMENTED THE BETTER HEARTS BETTER CITIES PROJECT. THE PROJECT'S AMBITIOUS AIM IS TO IMPROVE THE HYPERTENSION CONTROL RATE IN DAKAR. IN VIETNAM, PATH IMPLEMENTED THE COMMUNITIES FOR HEALTHY HEARTS PROJECT TO IMPROVE BLOOD PRESSURE CONTROL AMONG ADULTS BY INCREASING ACCESS TO AND USE OF HIGH-QUALITY HYPERTENSION SERVICES THAT ARE SUSTAINABLE AND SCALABLE. THE PROJECT DIRECTLY BENEFITS 700,000 PEOPLE IN FOUR DISTRICTS IN HO CHI MINH CITY. BY THE END OF 2018, NEARLY 33 PERCENT OF PEOPLE SCREENED WERE FOUND TO HAVE HIGH BLOOD PRESSURE MEASUREMENTS AND WERE REFERRED FOR HYPERTENSION DIAGNOSIS, TREATMENT, AND MANAGEMENT (IF REQUIRED). PATH IS ALSO IMPLEMENTING A PROJECT FOCUSED ON HYPERTENSION SCREENING IN URBAN SLUMS IN MUMBAI, INDIA, IN PARTNERSHIP WITH RESOLVE TO SAVE LIVES. THE PROJECT USES A PRIVATE-SECTOR ENGAGEMENT MODEL TO IMPROVE HYPERTENSION SCREENING, DIAGNOSIS, AND CARE. IN ADDITION, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO PREVENTION AND CARE FOR PEOPLE AT RISK FOR OR LIVING WITH THESE DISEASES. HEALTH SYSTEMS INNOVATION AND DELIVERY PATH'S HEALTH SYSTEMS INNOVATION AND DELIVERY PROGRAM IMPROVES THE HEALTH AND WELL-BEING OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES BY STRENGTHENING HEALTH SYSTEMS AND ENHANCING COUNTRY CAPACITY FOR DATA-DRIVEN DECISION-MAKING. OUR PORTFOLIO SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS, INITIATIVES, AND UNITS THAT STRENGTHEN HEALTH SYSTEMS. THE HEALTH SYSTEMS ANALYTICS UNIT PROMOTES SYSTEMS THINKING IN THE DESIGN, IMPLEMENTATION, SCALE-UP, AND EVALUATION OF HEALTH PROGRAMS AND TECHNOLOGIES. WITHIN AND OUTSIDE OF PATH, THIS UNIT LEADS COMPLEX EVALUATIONS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES HEALTH TECHNOLOGY INTRODUCTION AND SCALE-UP, AND WORKS TO IMPROVE DATA QUALITY AND USE FOR DECISION-MAKING. IN 2018, AS PART OF THE GLOBAL FUND'S PROSPECTIVE COUNTRY EVALUATIONS, THE UNIT CONTINUED EVALUATING THE GLOBAL FUND'S BUSINESS MODEL IN THE DRC, GUATEMALA, AND UGANDA USING A MIXED-METHODS APPROACH. STAFF ENGAGED IN SEVERAL NETWORK ANALYSES TO INFORM THE OPTIMAL STRUCTURE AND FUNCTION OF VARIOUS COALITIONS AND INFORMAL AND FORMAL NETWORKS. PATH STAFF CONTRIBUTED TECHNICAL EXPERTISE TO THE EXPANDED PROGRAM ON IMMUNIZATION'S LEADERSHIP AND MANAGEMENT PROGRAM, LED BY YALE UNIVERSITY AND FUNDED BY GAVI, THE VACCINE ALLIANCE. THE HEALTH SYSTEMS STRENGTHENING IMPACT TEAM CONTINUED TO SERVE AS A HUB FOR STAFF WORKING IN HEALTH SYSTEMS. THE GROUP CONVENED TO PLAN FOR FUTURE WORK IN STRENGTHENING URBAN HEALTH SYSTEMS, IMPROVING COMMUNITY-LEVEL DATA USE, AND DEVELOPING RESOURCES FOR SUCCESSFUL INTRODUCTION AND SCALE-UP OF INTERVENTIONS AND TECHNOLOGIES. THIS TEAM ALSO DEVELOPED PATH'S PRIMARY HEALTH CARE STRATEGY. THE GLOBAL HEALTH SECURITY TEAM CONTINUED TO INNOVATE SYSTEMS FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE |
| FORM 990, PART III, LINE 4A | OUTBREAKS. WITH SUPPORT FROM THE US CENTERS FOR DISEASE CONTROL AND PREVENTION, THE TEAM WORKED WITH NATIONAL LEADERS IN THE DRC, SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR PUBLIC HEALTH SYSTEMS AND BUILD THEIR CAPACITY IN EPIDEMIC PREPAREDNESS AND RESPONSE. THE TEAM ALSO BEGAN WORK AS A MAJOR SUBGRANTEE UNDER ICF INTERNATIONAL FOR SURVEILLANCE ACTIVITIES IN THE USAID-SUPPORTED INFECTIOUS DISEASE DETECTION & SURVEILLANCE PROJECT. THIS PROJECT WORKS TO IMPROVE THE DETECTION OF HIGH-PRIORITY INFECTIOUS DISEASES AND IDENTIFICATION OF ANTIMICROBIAL RESISTANCE THROUGH IMPROVED DIAGNOSTIC AND SURVEILLANCE SYSTEMS. OUR CROSS-ORGANIZATIONAL IMPACT TEAM FOCUSING ON EPIDEMIC PREPAREDNESS AND RESPONSE CONTINUED TO BE AT THE FOREFRONT OF THE EBOLA RESPONSE IN THE DRC, PROVIDING A KEY ROLE IN SURVEILLANCE, DETECTION, AND RESOURCE MOBILIZATION. THE TEAM IS DEVELOPING AND INTRODUCING INNOVATIONS TO STRENGTHEN ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING NOVEL VACCINE PLATFORMS, PREPARING MEDICAL COUNTERMEASURES FOR PANDEMIC INFLUENZA, AND DEFINING PATH'S ROLE IN COMBATING ANTIMICROBIAL RESISTANCE. DIGITAL HEALTH SOLUTIONS PATH USES INFORMATION AND COMMUNICATION TECHNOLOGIES TO IMPROVE HEALTH AND SAVE LIVES. IN 2018, OUR GROWING DIGITAL HEALTH TEAM APPLIED ITS EXPERTISE TO SEVERAL PROJECTS. KEY ACCOMPLISHMENTS INCLUDED LAUNCHING THE WHO-PATH STRATEGIC COLLABORATION ON INNOVATION AND GLOBAL DIGITAL HEALTH. THIS COLLABORATION WILL BRING TOGETHER A CROSS-SECTOR NETWORK OF DIGITAL HEALTH EXPERTS AND INVESTORS TO SUPPORT WHO IN DEVELOPING A GLOBAL DIGITAL HEALTH PORTFOLIO. PATH ALSO LAUNCHED THE CENTER OF DIGITAL AND DATA EXCELLENCE, A BODY DESIGNED TO COORDINATE DIGITAL HEALTH EFFORTS ACROSS PATH. WE CONTINUED WORK UNDER DIGITAL SQUARE, A PATH-LED INITIATIVE. THIS IS A PARTNERSHIP OF THE WORLD'S LEADING DIGITAL HEALTH EXPERTS FROM MORE THAN 40 ORGANIZATIONS AND COUNTRIES WORKING TOGETHER TO STRENGTHEN DIGITAL HEALTH SYSTEMS IN EMERGING ECONOMIES. IN ADDITION, WE COLLABORATED WITH THE JOINT LEARNING NETWORK FOR UNIVERSAL HEALTH COVERAGE TO CONTINUE A PEER LEARNING NETWORK THAT INCLUDES PROFESSIONALS FROM MINISTRIES OF HEALTH AND NATIONAL HEALTH INSURANCE AGENCIES IN TEN COUNTRIES. THESE PROFESSIONALS ARE WORKING TO IMPROVE THEIR HEALTH CARE DATA SYSTEMS, WHICH WILL HELP THEIR COUNTRIES ACHIEVE UNIVERSAL HEALTH COVERAGE. WE CONTINUED IMPLEMENTATION OF THE TANZANIA DATA USE PARTNERSHIP, WHICH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE COUNTRYWIDE HEALTH INFORMATION SYSTEMS AND IMPLEMENT ITS DIGITAL HEALTH INVESTMENT ROAD MAP. THE BID INITIATIVE, A COLLABORATION BETWEEN PATH AND THE GOVERNMENTS OF TANZANIA AND ZAMBIA, HAS EMPOWERED THESE COUNTRY GOVERNMENTS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. THIS PROJECT ENDED IN 2018, AND PROJECT CLOSE-OUT ACTIVITIES INCLUDED THE DOCUMENTATION AND SHARING OF PROJECT LEARNINGS. THE DIGITAL HEALTH TEAM ALSO SUPPORTED THE IMMUNIZATION DATA: EVIDENCE FOR ACTION REVIEW. THIS INITIATIVE REVIEWED AVAILABLE EVIDENCE ON WHAT WORKS TO IMPROVE THE USE OF IMMUNIZATION DATA, SYNTHESIZED THE FINDINGS, AND DISTRIBUTED THE FINDINGS THROUGH AN ADVOCACY AND COMMUNICATIONS CAMPAIGN. COUNTRY PROGRAMS PATH'S COUNTRY PROGRAMS SUPPORT WORK RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTICOUNTRY EFFORTS. IN 2018, WE OPERATED FULL-SCALE "COUNTRY" OFFICES IN THE DRC, ETHIOPIA, INDIA, KENYA, MYANMAR, SENEGAL, TANZANIA, UGANDA, UKRAINE, VIETNAM, AND ZAMBIA, AS WELL AS SMALLER "PROJECT" OFFICES IN MANY OTHER COUNTRIES. EXAMPLES OF OUR COUNTRY PROGRAM WORK ARE HIGHLIGHTED BELOW, FOCUSING ON THE DRC, KENYA, AND INDIA. IN RESPONSE TO RECURRING EBOLA OUTBREAKS IN THE DRC, PATH HAS FOCUSED ON STRENGTHENING GLOBAL HEALTH SECURITY AND EPIDEMIC PREPAREDNESS IN COLLABORATION WITH THE MINISTRY OF HEALTH (MOH). IN MAY 2018, THE DRC EXPERIENCED ITS SECOND EBOLA OUTBREAK IN LESS THAN 12 MONTHS. IN COLLABORATION WITH THE MOH, PATH DEPLOYED THE FIRST WAVE OF 12 MOH INVESTIGATORS, 10 EPIDEMIOLOGISTS, AND 6 COMMUNICATIONS EXPERTS TO THE CITY OF MBANDAKA TO ASSESS THE OUTBREAK. PATH ALSO ADVISED THE MOH ON IMPLEMENTATION OF A STRATEGY FOR DATA COLLECTION. THIS METHOD USED SATELLITE IMAGERY TO REFINE MAPS SO THE MOH, PATH, AND OTHER KEY PARTNERS COULD BETTER TRACK THE OUTBREAK. UNDER A GLOBAL HEALTH SECURITY EBOLA OUTBREAK RESPONSE GRANT, PATH CONTINUED TO PROVIDE SUPPORT THROUGHOUT THE 2018 OUTBREAK, BUILDING DATA MANAGEMENT AND VISUALIZATION CAPACITY AT THE EMERGENCY OPERATIONS CENTER IN KINSHASA AND COORDINATING WORK ACROSS KEY RESPONDERS, SUCH AS WHO, THE UNITED NATIONS OFFICE FOR THE COORDINATION OF HUMANITARIAN AFFAIRS, AND THE US CENTERS FOR DISEASE CONTROL AND PREVENTION. CONCURRENTLY, PATH CONTINUED TO EXPAND SCREENING FOR HUMAN AFRICAN TRYPANOSOMIASIS (HAT; ALSO CALLED SLEEPING SICKNESS) IN BANDUNDU PROVINCE. IN RECENT YEARS, UP TO 60 TO 80 PERCENT OF ALL CASES WORLDWIDE HAVE BEEN REPORTED FROM THE DRC. RESEARCH HAS SHOWN THAT DISEASE CONTROL HINGES ON ACTIVE POPULATION SCREENING AND VECTOR CONTROL. IN 2018, THIS PROJECT FOCUSED ON EXPANDING ANNUAL SCREENING CAPACITY TO ENSURE THAT AS CASES DECLINE, PEOPLE CONTINUE TO PARTICIPATE IN SCREENINGS. IN PARTNERSHIP WITH PATH AND REGIONAL STAKEHOLDERS, THE MOH ESTABLISHED THE FIRST NATIONAL HAT ELIMINATION DAY ON JANUARY 30, 2018, RE-INVIGORATING LOCAL AUTHORITIES TO ACHIEVE THE GOAL OF ELIMINATION. PATH'S WORK TO IMPROVE HIV/AIDS SERVICE DELIVERY IN THE DRC WAS FIRST CONDUCTED THROUGH THE USAID-FUNDED PROVIC PROJECT AND THEN THROUGH ITS FOLLOW-ON, THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA AND LUALABA. FROM APRIL 2017 THROUGH JUNE 2018, THE PROJECT TESTED AND INFORMED MORE THAN 286,000 PEOPLE OF THEIR HIV STATUS AND ENROLLED MORE THAN 97 PERCENT OF IDENTIFIED HIV-POSITIVE INDIVIDUALS ON ANTIRETROVIRAL THERAPY. IN KENYA, PATH WORKED TO IMPROVE HIV PREVENTION AND TREATMENT THROUGH A PROJECT CALLED "IMPLEMENTING ASSISTED PARTNER SERVICES SCALE-UP STUDY TO HIV TEST AND TREAT MEN." IN 2018, PROJECT START-UP AND IMPLEMENTATION ACTIVITIES FOCUSED ON ENROLLMENT OF WOMEN AND THEIR MALE SEXUAL CONTACTS IN TWO COUNTIES IN WESTERN KENYA WITH A HIGH HIV BURDEN. WOMEN RECEIVED COUNSELING ON PARTNER NOTIFICATION AND PARTNER ELICITATION CONDUCTED BY THE HIV TESTING SERVICE PROVIDER. ELICITED MALE SEXUAL PARTNERS WERE THEN CONTACTED, NOTIFIED OF THE HIV EXPOSURE, AND OFFERED HIV TESTING. ALL CLIENTS NEWLY IDENTIFIED WERE LINKED TO CARE AND STARTED ON ANTIRETROVIRAL THERAPY. EACH ENROLLED PARTICIPANT WAS FOLLOWED UP PERIODICALLY TO ASSESS HIS OR HER LINKAGE TO CARE, ANTIRETROVIRAL TREATMENT INITIATION, AND VIRAL SUPPRESSION. ALL IDENTIFIED PARTNERS WHO DID NOT HAVE HIV WERE REFERRED FOR PRE-EXPOSURE PROPHYLAXIS TO HELP PREVENT FUTURE INFECTION. PATH ALSO CONTINUED WORK UNDER THE APHIAPLUS PROJECT TO HELP INTEGRATE SERVICE DELIVERY FOR HIV/AIDS AND OTHER HEALTH CONCERNS AND INCREASE THE AVAILABILITY OF SERVICES FOR MARGINALIZED POPULATIONS IN WESTERN KENYA. FROM 2011 THROUGH JUNE 2018, APHIAPLUS AND THE PATH-LED AFYA ZIWANI PROJECT PROVIDED HIV TESTING SERVICES TO MORE THAN 6.7 MILLION INDIVIDUALS IN KENYA, IDENTIFIED MORE THAN 102,600 NEW HIV-POSITIVE INDIVIDUALS, AND SUPPORTED MORE THAN 120,000 PEOPLE LIVING WITH HIV/AIDS ON ANTIRETROVIRAL THERAPY, WITH MORE THAN 80 PERCENT ACHIEVING VIRAL SUPPRESSION. TO STRENGTHEN NEWBORN NUTRITION IN KENYA, PATH IMPLEMENTED A PROJECT CALLED THE "MOTHER-BABY FRIENDLY INITIATIVE-PLUS MODEL FOR HUMAN MILK BANKING." FOR VULNERABLE INFANTS, PATH ADVOCATED FOR A HOLISTIC APPROACH OF BREASTFEEDING PROMOTION AND PROVISION OF SAFE DONOR HUMAN MILK WHEN A MOTHER'S MILK IS NOT AVAILABLE. IN 2018, THE PROJECT WORKED TO ESTABLISH LOCAL OWNERSHIP AND TECHNICAL COMPETENCY IN HUMAN MILK BANKING BY DEVELOPING LEARNING EXCHANGES, CONDUCTING FORMATIVE ASSESSMENTS, AND DEVELOPING A COUNTRY-SPECIFIC STRATEGY FOR HUMAN MILK BANKING. THE PROJECT THEN WORKED TO OPERATIONALIZE THIS STRATEGY TO SET UP A HUMAN MILK BANK FOR LAUNCH IN MARCH 2019. IN INDIA, PATH HAS HELPED TO IMPROVE CHILD NUTRITION THROUGH RICE FORTIFICATION. FOR A DECADE, PATH HAS WORKED CLOSELY WITH INDIAN PARTNERS ON THE FORMULATION OF A FORTIFIED RICE PRODUCT (ULTRA RICE) TO REDUCE THE PREVALENCE OF ANEMIA AND MICRONUTRIENT DEFICIENCIES. IN 2018, PATH WORKED WITH LOCAL PROVIDERS TO BRING FORTIFIED RICE TO SCHOOLCHILDREN ACROSS THE STATE OF GUJARAT. THIS FORTIFIED RICE PROVIDED CHILDREN WITH VITAL MICRONUTRIENTS THAT MAY OTHERWISE BE LACKING IN THEIR DIETS, INCLUDING IRON, FOLIC ACID, VITAMIN A, AND B COMPLEX VITAMINS. IN THE STATE OF UTTAR PRADESH, PATH SUPPORTED LOCAL GOVERNMENT EFFORTS TO ELIMINATE VISCERAL LEISHMANIASIS, ALSO KNOWN AS KALA-AZAR, IN NINE AFFECTED DISTRICTS. KALA-AZAR IS A PARASITIC DISEASE TRANSMITTED BY INFECTED SAND FLIES THAT HAS A HIGH FATALITY RATE WITHOUT PROPER TREATMENT. IN 2018, PATH DEVELOPED TOOLS TO ASSESS THE USE OF PREVENTIVE MEASURES, SUCH AS INDOOR RESIDUAL SPRAYING, AND THE AVAILABILITY |
| FORM 990, PART III, LINE 4A | OF DIAGNOSTIC KITS AND DRUGS TO TREAT THE DISEASE. THE PROJECT ALSO STRENGTHENED THE QUALITY OF SURVEILLANCE SYSTEMS BY BUILDING THE CAPACITY OF LOCAL GOVERNMENT. WE SUPPORTED THE GOVERNMENT TO REGULARLY PERFORM DATA QUALITY CHECKS AND CONDUCT DATA VISUALIZATION TO IDENTIFY NEWLY AFFECTED VILLAGES. THIS ENABLED MORE TIMELY DECISION-MAKING AND ACTIONS ON PREVENTION AND TREATMENT. PATH ALSO CONTINUED INNOVATIVE URBAN TB CONTROL EFFORTS IN INDIA. THE PPIA PROJECT, WORKING TO ENHANCE THE ROLE OF PRIVATE HEALTH CARE PROVIDERS IN TB CONTROL, PROVIDED FREE OR SUBSIDIZED SERVICES TO PATIENTS IN MUMBAI WHO WOULD OTHERWISE BE UNABLE TO AFFORD THIS CARE. FROM THE PROJECT'S LAUNCH THROUGH 2018, 202,468 PRESUMPTIVE TB CASES WERE SCREENED AFTER BEING REFERRED FROM THE PRIVATE SECTOR, AND 62,633 PEOPLE (31 PERCENT) WERE DIAGNOSED AND NOTIFIED. A TOTAL OF 49,856 PATIENTS WERE SUPPORTED FOR TREATMENT ADHERENCE MONITORING, AND 2,790 TB PATIENTS WERE LINKED TO PUBLIC-SECTOR SUPPORT. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF OF ACCOUNTING SIGNED THE FORM. |
| FORM 990, PART VI, SECTION B, LINE 12C | PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2017. AT THE REQUEST OF THE BOARD, PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE VICE PRESIDENTS AND EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. |
| FORM 990, PART VI, SECTION C, LINE 19 | PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. |
| FORM 990, PART XI, LINE 9: | FOR THE YEAR ENDED DECEMBER 31, 2018, THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS UPDATE (ASU) NO. 2018-08 - NOT-FOR-PROFIT ENTITIES (TOPIC 958): CLARIFYING THE SCOPE AND THE ACCOUNTING GUIDANCE FOR CONTRIBUTIONS RECEIVED AND CONTRIBUTIONS MADE FOR REVENUE TRANSACTIONS. THE UPDATE ASSISTS ENTITIES IN (1) EVALUATING WHETHER TRANSACTIONS SHOULD BE ACCOUNTED FOR AS CONTRIBUTIONS (NONRECIPROCAL TRANSACTIONS) OR AS EXCHANGE (RECIPROCAL) TRANSACTIONS AND (2) DETERMINING WHETHER A CONTRIBUTION IS CONDITIONAL. THE PRIMARY EFFECT OF ADOPTION OF THIS ASU FOR THE ORGANIZATION IS THAT CERTAIN AWARDS RECEIVED THAT WERE PREVIOUSLY TREATED AS UNCONDITIONAL ARE NOW TREATED AS CONDITIONAL. AS A RESULT, REVENUE FOR THESE AWARDS IS RECOGNIZED WHEN THE CONDITIONS ARE MET DURING THE AWARD TERM, WHEREAS PREVIOUSLY REVENUE HAD BEEN RECOGNIZED WHEN THE AWARDS WERE AWARDED. PATH HAS ELECTED TO ADOPT THE CHANGES FROM THIS ASU RETROSPECTIVELY TO THE 2017 FINANCIAL STATEMENTS. THE NET EFFECT OF THIS CHANGE IS PRESENTED AS AN OTHER CHANGE IN NET ASSETS. -378,755,643. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATH VACCINE SOLUTIONS | ||||||||||||||
| 2201 WESTLAKE AVENUE | SEATTLE | WA | 98109 | 830431851 | ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN | WA | 501(C)(3) | LINE 12A, I | PATH | Yes (1) | ||||
| PATH DRUG SOLUTIONS | ||||||||||||||
| 280 UTAH AVENUE SUITE 250 | SAN FRANCISCO | CA | 94080 | 943384500 | DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES | CA | 501(C)(3) | LINE 12A, I | PATH | Yes (1) | ||||
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | 207 ROUTE DE FERNEY 1218 LE GRAND-S | GENEVA | SZ | SZ | |||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | Yes (1) | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (4 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| PATH VACCINE SOLUTIONS | ||
| C | $20,062,779 | FMV |
| PATH DRUG SOLUTIONS | ||
| C | $2,964,636 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| C | $520,410 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| B | $3,321,058 | FMV |